var title_f3_34_3616="Bronchogenic carcinoma CT VII";
var content_f3_34_3616=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchogenic carcinoma with amorphous calcification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADvAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5VpaSloAB1oopVBYhV5JoATGa67wbpEha4uby0xDsIV5lIGeOQDXOJcC2QrbbS5HM235hxyFz0+vX+VJbXDI5ZpDx29aAOx1zU4oY5RpscVvI/Es8YIdx6Z9P/rVxDnJzkk570+e4eZyTwPQUQWs1w4WKJ2J6YUmgCIZPSnRxvI4VFYknGAK67R/B5uNr3cnlp1OUPr0612+ladoWjQjzY4nkBx5jDOKAPP8AQvBmo6m4MytaQZGZJF7HvjvXc6R4B0uyUPeL9qlA3HeuF/n/AD/+tXTWOpW07KYSjRryCR9f8afLrGmwr5bXESEDcS42j8j+VAENr4e0zaFFjZqCAoUQKAeOvSmXegaLBAzyaZYkx9f9HXnjvxWJH4pQ3BWCS12jgsGBx7da57XtUtrsSGTWo/m6xoCccUAdDNa6Mm3do9lGBzk2ykEfXHuKhurbR4xGTpNoN3Ct9lUA8D29Ofxrz+dLYfNbaqsoYcggr+hpsz3uwtDcGYDIyrZxQB0mpXOlrdCNdNslXJXctuoHUe31qqG06ReLO1VgOghXn8xXPWTSXd/Cl6xVM/M7cYFbugW0GpyXdv58KBA3lszAZAI5GTQBQe4g+0eV9gs8E4X9zjIz610XhfQtLvte0/T9R8lJbi5ihESRfeLMBjP/ANeuUe38q6YGVXSNiNwOQcGtbwTqEVl4v0e8umVYbe+gmdiPuqHBJ/KgD6ai+FHw+a2ikGjW8kRUbXSaQhhyM53c9OtV5/hT8NhkSaRGGBAO25nGOPZ67xoodWtI7i2uFaCRQVdBuDqe+QR2qm3g+2cMzNICchj5fJ4+vrQB5tq/gr4Q6QH+26btZeCBcXbYyOvD1Q0/w/8AB3UGdbHRjcbBuOLi6HHHrIDjmvS9a+H2j6rbTRzxyAyDG9RyvFQ+HPhtougeYbaNn3KQ3mLnA4zjmgDnLD4Z/DO7ZUTw3Hll3Am7u+QMHOfNxUvif4MeC10qU6X4cihulOQftV0SeeRhpSK9Dlh07SLZp5zDaW8QYtJNhFTHOck4HFZ1h458L6kZhY65YTCEkv8APjHOM89R7igDyjwl8O/Blzvt9R8N2skwJ2u11dqSMjghZQO9dTH8IvAoBL+FLR8Hol3eAgen+u5NOf4meAbF7y4gvYGvcspiitpN8jA8Bflx+Oa4LVP2gnMjrpXhzy8H5WuZvu89wBx9M0AHjXwR4O067Mdn4ct7dAozm6uSc+ozLzXKHwv4eWIPLo2wFuolmIx2/jo8WfErT/EumP8AbrCJdT2bVkV+F5HQ4+tecPqdxIuH1FgMYxlj+FAHp8Pg7wxMQxskSM4BxPLwTjB+99ast8OfDjDckUmPRZX/AMa8vtPEs1r8vnSyAcA9M8Yrb0vx88EqrKrrEfvNtBIoA6u5+GOhmeRQ97EqrnCuOOnPINVb74VaeUb7DeXqtjIMu1gePZRWnB4ztdRmb7Ld28wClmVlaMoABn72P8/jWrpviKC7ilEciYUZO3J7cmgDxXxB4X1LRJnF1byeUGIEgHynn1rE2D3B9CK+kYPs2ogRMIpllPKsu4HBzXGeL/h/DcKZ9LcRzKCWgEfXntzx+VAHkXl8HGTVuxtbS4+Sa4NvIR8rMMrn0OOQPei+sLmwmaO5heN1OCGXFVe4yKAC4t5beTy543jfAOGGOD0P0qPFaVsiXfl29zKsRUfJLtzgc/Kcds/lVK4t5baXy7iNo3xkA9x2IPce9AEWKMUtFACYox70Gj/PSgBMUUtFAABRRSgZIA70AKilyAo5pWxt2qBjOc45NO3BU2r1PU/57Uwe9ACVLbwSXD7IkLN7VZ07Tpr2QCNTt9cj0r1Hwx4ImjiEkkTKG7/L044oA4/SPC+QXvWIOPuY5/Wta+ls9LhCW8a+aeOAPbr+dXvE93ZWLSR3LOhiJGxRySRwOtcDq2sPe7Y4oxFEv4s31NAGnda48UmGkIxxtT+vNZ9xr08khYIp93ySf1rHooAu3OqXdxgNMyoOioSBVNiWOWJJ9TzSUUAFFFFABRj2oooAMCjHtR1o/CgBQTtIBIB7UgFLVy00y8u7eS4trdpIUIVnGMAmgCOyvbqxlMljcz2zkYLQyFCR9QaRY5ryTe5ZyTy7En+tTrp8oAZ146Hpwav2+1FVYwGOAcHoOKANiO51YaSsY1SeK1ToiysueOuAec/1qjP4s1CK1Fta3dwSAwMzyNu5AyBzx0rPuhPgDI2//WqnNakqHXgt2PFAEVxdXFzJvuZ5ZnH8Ujlj+tNM0rD5pGI+tNdGQ4cYptAD3lkbkuaYTnOST9aTvR2oAAKKKKACiiigAp8MskEgkhdo3HRlODTKKAOx8KeL5bHUI/tu3ymIDSrwR9a9MsNW+2SRGKaOWFwSHTBAJP1rwKrOnX1xp10txZymOVe46H2I7igD6G1vQLLWtOlguI4RMAAsojG5TnseteI+KfDd3oV2yTKGiPKSKMhq9M8E+K59U03zriP95G3lysMBc5yCB9MV1Fxb2GvWElvOiSLx1A4P17UAfN2CcHGcVqW99G9mLG7gSSEvuD7f3i8Y4bsPbpWl4v8ADM+gXuNubdxlHyCD+Xf2rnGG4d80ASX1kbba8bGW2Y4SXGMnGSCMnBqpVyGQpEysN0bDDAjPbt6EUy+tTblXXc0EmfLc4ycYyCPUZoArUUGjvQAlFLRQAlSY2g5xuI+uKSP5cMevUCk6Hn+dACgZIA61uaFoE+oOp2EKTj68Vb8H6BJqN7CzIXBIKoOrfpX0p4F8Dw6VDBeXeDd4yEBG1cr9OvJoA5vwD8PYbK3in1G34zuWMqDu46tn/PSs/wCM/jeHw1E2g6OUbVpE/fuApW3Qjgf7xHOOwOe9dl8XPHEfgrw8zW0kLa3d5jtohIu+EFT++KkHKgjHIwTx2OPkm6uZru5luLqV5p5WLySO2WZj1JNADJZGlkaSRizscknvTaKKACiiigAooooAKKKKACiiigA/GrOm2NzqV7DaWMTS3ErBVUep9T2HvTtKsZ9T1G2sbUAzzuEXPQZ7n2r6Z+G3gi08ORR7W8y9dcSSED1zgcdKAOU+H/wai823uvEjecwOTbIfkz6E45/z1r1xPDenQ2yW9vZ20VoFwscSKoBz6Ditq3QLGAAPc/jUmGK/K5GCD16/560AedeMPh9b6pp6rbqkcykHKoozweD3rwzxL4Xv9CuWDwsYhzwM4/zivrtCQVUn5cetcx4s0RNRgLI22RcsCPTHcYoA+RWd1O4jGR0wKLi43RgNjgegrufEWgRW0zQ4OOecjIOOnSuPvLMQuRuyMZ470AUY2DEq4BB7EZrSlstOvIAtsTBdA/eLfIw9x2qi0RUnpTzFKACOuP60AZ95aTWcxiuE2sO/Y/Q1BxW2buQhBOBIq9mqpewRO5ltmCBvmMbHGDn+H2oAzzRTtjgE7GwvJOOBTaACiiu88E/D6XXLEajfTeTZsD5aIfnfrz0IA4oA4uwsrnULlbeziaWZuij+p7V6Xofw+sxoqy6msr6i+WZN4Ecajp06nr3/APr9X4c8PWujtPDaQIJdpXJOc/U/hXZ2WnYgJKjAGAM8A4oA8Y8R+ALGLT4Z9HuJ/tLHDwyAFDyPunqP1/DFQaD8Ohc3DpqV4Qqr923IJDZHBJ46Z/SvWdXsD5WS23PPyDhfU1jWEMkbHa5Zj8xIOM/N14oATwh8PbHSLiY/bZ5UmjCtG4Uruz3wKtNotzp98ZIW3RKAMEjJHX/OavvPPZqXRyoUZznIxVyPUA8UZZixZQev8+KAIZ9PstY03yLyNGVhxkD5Djt+deGeMPDM2h38keAybsKQc5Fe9BWikLRk7XPOxRjqeOlM8TeGBrOmRNLgJuVg45OQp9vSgD5jkTZyelTW8gRWjmUNC4wQQCQccEehFdv448Hvo6pMuSj+hBFcTKp2DA74wT0oAqXMBhkxnch5Vh0IqKtEDchtZWyv3lIP3WI6/T1qhKjRStG2NynBxQAyilooAegyB69K19C0qS8n3bNyqRkZxUWg2Bv7iNdvyhgCee5r3j4ZeE0kvY5WA8m32O4wcFs8Dpz0zQB2nwz8IRaFYw3cuWu5Y1bngJkZx9ea7CbUrC3trq5u762itbPm4d5BiH5Q2G9GwynB5+YetTBsFUGAT75Hc/yr5/8A2k/GUdxLH4Ts1J+zyJc3coJHzbTsj6cgBgx6847g0AeS+N/Elz4t8TXmsXa+WZyBHFu3CKMDCqDgZwBycDJye9YVFFABRRRQAUUUUAFFFFABRRRQAUUHpSigD2P9n/QFlurrWp2IC/uIQO/OWJ/IfrX0NaRLHGM4BxjOcd68v+AUA/4QmzZY2+d5GY9j+8Yf0FepqViUBQSu5m5JPLNk8ntk9BwBwAAAKAJMnO5z9OR60oYbN278jUDuN5ADdfekjBPYjpnn+VAE6yfOucAfWpFwydecjGD7VFGCD93PcjJOetSxknbwc4xjPtQB5H8WNLSzk+1DHly8Yz0bHrXjdvAb/UPJhIJHTvx/nFfS3xK09bvwjfo6gssbOuST8wGa8y+DXhgXlzJqF3FuiAKjcCMnKnI/OgCXR/huJYA7/fwD8x/+tU+q+AkS2CsPm5wQcc5r26G3SKMIFG0LjH9KZcWiSIQ446dTigD5P13wvcWoYoCUX2+79a4+8tjGfmJGOK+o/GGkhrScBCoUZX/63rXgOuaQ8t+0duASznjn1PFAHISGRrYgMREpG4Z6+lVK6XUki0rTr2xu7ctdT+UYnJP7vDZJ/EcVzVAAelfT3g+3A8J6SIWDf6LEA8ZDAkIOf0r5hr2P4F63Psl057qQpGS0cZJwn09P8aAPadM0aESmViMryF7irUsO3zCZBsxnPqamtbtRH94Bs4GTz+NPkRWmwjZXPbnFAGK9rJK4cAEOcHPp7VrweGYpl3zf6wAjg8D6fnWxp9kflI3YXOFBOetbwjAA4IA+vrQB5r4g0WJLRkk3NxtVmIwOeRXOQxFR9nwFUBAMtyeen+fU163rNnJNb7IhgY68nvXBz2TrMMoHTI65PsT9O1AFFSFRFZuAoGQchTzWx4W1AQ3AtLtk+zuTh93Ctjv6VWW3JdcDgDnk88daoau4tLcOADCSA5GSBkZoA3/E3hiOe1dQu+JuoB5GQf8AGvnL4heEJtCvjLAS9vJnGOSMdc19T+D9TXUtM8qZlM0OFYk5LLtyGP8AL8KqeNdCjurG4Kwl12sGXBJGRQB8VyryWxh+eBUbsbpUjJHmKMJjHPsa6/xpoEmn6tOscbKgJIHPT8q42VSrFugznNAFYggkHgjjB7UVYnPnL5gB3jJf3560UAegeA7KJNIiuGizJJnnPoTg19G+BdNGnaFDJt/ezosjDkZ64HtXgXgO2efT9MijONxUEEE/ebFfTESi3tkhjI2oqoMnsMCgCh4o12y8L6HeaxqjEQQr8qg/NI/O1B7k4Ht34Br4o1S/utU1G4vr+Z5rq4cySOxJJJ+v5V7L+014hkk1LTvDcBj+yW8SXcoAOfNO8KPoEOeP79eIUAFFFFABRRRQAUUUUAFFFFABRRRQAUtJS0AfU/wLRYPhppcxIBk83nntM4ruJZFeRSNpZQQpxkgEjOPQHaPyFeU/BnUZ5/B2n2MQmLW/mIV2kjLSs+R+dek2aPHjzC27JGOgPegDTgJdAwz1z39asLGGbcv3sZzzTYh8nyg88gEnntzVpDkDPfrnOaAGnKqAOgxjPJ70kalCOPxbP51YUAqNuQOPXFVrueK1XzJX2KD1PToaAMnxcC+izwqSHlBTjPORjGKPCekroulpaRoMKM8dzgVySeK7fX/Ftpp9qQ9uhLs6g8kL/KvR41CnOFA9etAE4YlieR6HmpGThcjocHrzUaqctk/MO/NTqnORkA8eg6/WgDnvE8CtaMX2gdSSCa8N1C7sNO14OkAf95yWJyDuOeMdute7eL0H9mOW+8OQGzyew/WvnvWtHR9a8yadtrSglcEHlj0oA574u6E+m3en30au1reRkq5BwD6fka8+719KfEDw1Hrnw8vTZ/aLm8sEjmtlGTk7gHGO/wAufyFeTaF8N7zVtOiukvoYt+PkZCSAR9aAODrV8M63caDqsd5bM5AyJI1cqJFx0P8AP8K3tc+HWu6cA9nbvqcRIGbSJncHHdRk4461xnbjpQB9N+FPFFhrNrLdWRkdVOxi+VKnAOCO/Ue1ei6EqPH5pJLP1zz6f5/GvjTQ9dvdGkJtn3QswZ4XztbpzwetfSXhzVWkWPy5XL7csMEjkZ69O9AHsduse3KjkirStuPGfTPp9P0rC024j8qMOxx0GQexraUoACmOSegOOTkn/PrQAtwwVGYj5RzyenNcFe3sEkga3V1c9mye9djfXUCRSCSQAHqBmvNp5BG8r2qllLZAOeaALrESMNkh4A4AOe/bFQywRTW5jdcpjndk/gaqQzxrKrlUbB6YI/KrcU0MgZS2Mtg547cZ+tADvDM9tocsTNIyQMdj5J4B6fXBxXo0wV0ZGUFWUqRzzxXyb8VPGGl6hZf2dol5NmOfLsgZVwARjnrz+HAr374SeLW8Y+C7fUJ9ou4mNtcFejSKFyfxBU/jQBy3xB8L27vdR/Zt7PGQrZPAx+tfOviDRZ9Pmw4YruIHGOlfZ3imxW7sTMgO+ME9DnHevDvG2kLLZv5MeCoYbyCSOR/gaAPBF+RwccDqOaKsajCYZ2Rs5UkZwRRQB698H7Z73VNDhwRHCq3B+Xrjn+Zr3W81OKO6aN3CbIxIXKnG3JDH6D5M/wC+Px8L+C1+lndTTOm5o7BNmV7/AFqP4m+NY/7HutPVG+3XS4V8D90CRuwe2VyvHYkd+QDybxHq8+va5e6pdhVmupC5VRgKOgA9gMCs6iigAooooAKKKKACiiigAooooAKKK9J+Bdjo954i1Btctbe7SCzaRIZ4w6n+82DxkCgDzetPw/o9xrWpLa2yMxxucqudo9ad4q+w/wDCQ350hStiZC0a4xtHcD2znFd98GrWcNdSpCrJKNmemTwcflzQB7j8MdCtNF0WO1iw0mMO2MEnJ611lzpySHfGcE8j5e9ZmgWhtYoiVGQMHA9//r1v7gTh15HXj3/lQBnPDNbodiebj0BwKq3es2tmub5lgc4xvz6//q/OtthuXgZyOh471zfjTw8niDS3tXZYycEMFyeCD6+1AFHUPHWlQbVScOx4AVSR+NeNePvFmp67I8MSiKzDggcgtwevPI5r0GL4Wf6rytQaMbQCTFkn/wAerRh+G9mkalnWXGOSvXjr1oA88+DdjJB4gWaRCXwRuI4HFfQ7rghu/fI7VxukeHotNula2iTHqABgfn/n3rsQuQMjJ5HYZoAmH5Yzwe/+f6U4sw6YJ+lRFjyTj8BVW4kkgaeWV4zDgbEEZBU55Jfccg8cbRjB5ORgA4z4laiPtdhYxsCSWZwQfUAf1rhdTijMzq8cZO0cbTkEGn+INRS/8bBZedgKqQfu8jtUOrOwuBHbRtNLIyqAuCeT60Adf4TvY7jT5bdSrZGwg5JPBFcd4ciuLN/s+0oynG0L8v6duldX4D8P3WmWF1eaoiJK20omc7Rk9T681nXd0lldfuUBJbG5Rg85oA34o2jt1d8AgA/3R+dfN/xO0v8AszxdeCOAQ205EkIVcKRgZxjjrmvew5u4I4wfnkIJPTbxyOtc58UtDXX9L06G0jT7RbkkyBe2OR+n6UAfPhr2L4M64kkD6dLKhu0LOquDlk+Xv9e1cxZfDPWr44tnt3f+7uHT161O/wAJvGNsj3MFpA/kseY7lFYYwcjJH+NAH0xHchY0CFhjgHB9f1rb02+E6jBwcHoO+f8A9deB+DfHF/eXlrpd2IpLyMsJH75BP4egr1rRbvCgdXIPXr1/z+dAE+rRmVmDMfvE9D83NYtxCM+Zj5iBnjhRn2ro5ohL8zMN2ckbeOvHc9qpXQhjjGVO0LknGf8APegDlLpytwgzjIyMDrXKeI/E8GmRNbzBhcghxGAVYjHc59qteNtRi0nT2u/tDAqDsULktnPFfP19fXN9K8t1K8jOcksetAEM7iWaSRVCh2LbR2z2r6S/ZauguhX1kHDB53nKlTwdsa/jxg4/wr5qrvfhF42/4RHxDB9oRDYTyBZnOcxg4G4UAfZ5iDJJGy5Ug9R1B/ya868Q2CRXM0borLuICkY4z6fTFejRcjIADY6DtXN+MLddscw2/NlWIUE9sUAfM3xQ8Nm2nF9bRAQOTuwMbTRXqnifSotR0m6jMSspUkFhn/8AVRQB4T4d1CbTmiMbFRLCEJwPSub1O6a8vpZmJOTxkdq7HVtCuYfCNnq0cX+jpDCZXUqCNyjHv1IH41wg6UAFFFFABRRRQAUUUUAFFFFABRRRQAe1SW8MlxMkUCM8rnCqoyTUde5fs9eGdMvtNvNYvYlluYbnyYw2CFAQHOD3+Y0AcQPhh4iKxSNa7YW+/IXGE6ZyOtezeGRpfh7w8Le2+bZncSBktgfn0r0FzbGBrYooJB4Kge1cjq/hSN02gPh2LnBGM8UAXtC1i4vGWRlLIc4bA45711drNKyq0igYz8oA9uf0/wA4553QrKLToI4oxxnoxHrnj8xXRROAu7GV6jGOKANKM7k4zkjj86aVJYHkADp/n8KhR0CAltoOOT0zmpe4Yj0x0oAEB3qN3zHpgfWlC5X09DUagA4HHpjjFPjXgFsegwfpQBSljAZSQeO3arMZBTPHA6jHPFQyqMZAHAx1HpUcswgRyzdAc9KALUsuyNmJ4xn8OKzb+QPC56ZyMnHGSK4/xB4ztbW62CeMEHBUkdPWoL3xZbrYkq+ZB1PHqBQBz934cln8RK9qQPMba/GMLkcV6JpeiWmm20btFHJOF++QGIOfWuL8H6jLqepCYqfI3YGQOeRXeXk+9lQZ2j6cjPAoAq3lzuIRgdrds+/UYrmdYs4jKH2sCcDIAHH17100lssnOSemDj9aqX9g4jV3R33DqCMY560Acjbu1lGwkjLOem73A/xp0NtO9mXmfOORx1znArJ8VeKNJ8Nhhdq89+xGLVWXIBGQzf3Rx+vQ1xfhLxrreveLLa3uJki08F5WgijUKoVSeuM9QO9AHr2hWq6FC6z8TS5JGQSF4OK19Nvo5pLiGV22bc4KjngDpXAXWoXeo37ygZTkAdNo9K39OnJlUNIzHpnAGfrQBxHxS8GiwkXWfDFu0VxESZo4RnPIwwX25zS/Cfx99smj0rV5Cbt2/dSsqgPyMD/e5/SvW50VoVkb/WHHzEjjmvDPi94at9LaLWNKiW1cyETJHtUDphgB0OaAPoGS7XyQobqBg8ev19q5vUNaG140yw4ySQAvPU9q+cLLxx4gsoFiivy6KMKJUV9v0yKpap4l1bVIDBe3ReJuqqoUHvzgc0Aeh+PfG+lmKWy06GLUJZEKM7qrRLkEcepH5V5IKKKACiiigD7M+BXiWXxP8PLS5vGZ7qzdrKZyAN5QKVPH+w6c+ua67xIgbTXLZBUg5/ED+tfNX7MviKTT/Fl5pM0+LK9t2dIyAR56lcH2+XcOOvHpX0d4ilB0K78tjlVGCT/tCgDhLuZPs8zMpA2kc4x/nFFZd5MG0y4uOreS5bJHv0ooAy9T0/8A4x4ufLLAtptpKVJ4OPLYkV83jpX1zDbCb4DFCcb/AA6p5A6i2BHb2r5GHSgAooooAKKKKACiiigAooooAKKKKACvfP2epWtPC+oyyHbA903P+6i/l1rwPtXvHwf13QYvBFxpV5qFvbTiVyy3EqxlgQDlcnn04oA7LTNeW/15pUK+UuQvzZzyK9Im2S2iksAMHkHHavJrCztLKCSSG6WWJGZlYSAhce4rp9Z8XWeleE0vmdGyNoAkXLH2oA3pE3OWHUHd+tSCcBggKgMeoPv06Vw/hz4kaHdKsd9qthBH/EZZgCefTtWnf+NPC8Yje21zSZSWPS6XI/CgDu7bBiUgjjt+NTH7xJPUAYJrL0LV7LVNPjuLS7t51xkNHIGHX1FaDXKAsoYZAHcUAKykEHgevPp2/X/PFEbDOc/X8vpUdxf28G0TXEaAjncwGMZ/z+dctrfj/Q9LBd7+KaTp5cLqzZ9cD6UAdTKyxQNI7KFUY5I9K8p+I3jyK23WWmypNKytuKPwpx64rhfGvxN1XXHkg00mys/u7Rgu4x3Pv6VwkhWANLeTsDgkLu+djigDp7W1k1S7Ekzma4J3HYeAPfitzULZNPjilabeC3QdB0rhdM8ZjTkmEempKXB2s8pBHpnA5HtxVC98Y6vdLtaS3SPJIRYhhfYZzQB73o3iGxsrWNTMjP2VW6EmumstUguQkjSIUwOFb3r5TXxLq8ZUx3rJjoFVQPyxVl/GniNrd7f+17hYn4Kphf1AzQB9VT6vb2du8t3LBBEuN0kkgC49/SvH/H/xlmkLWXhRtqqRuvXAbPXKqjLjHT5j+VeNT3lzOMT3M8g9HkLfzquaAJry6nvbqW6vJnmuJWLvI5yWPvXt/wAEvDLW3ha51u4RhLeyeXED/wA8l/i/Fs/981454f0mbW9Uhs4WWMOfmkbOFA5J4FfWGlNBbaBY2MAZorWBIIySNxVVA5/KgDmZraUzNFCAgAOSD1HtxTreylin2JINx5ZSeO361dk815ZAhZUPJDHgdOn+f6Vs6faRrG0jyBmBzknA/lQBKxi+x5YnCjJyPfpXknxivk/4R+aKSRQ8zKkMeRnAYEn34FVPiL8UruPWLnS9BjSG3tZXhkmYh/OII6DsMg+ufavLNb1q/wBauRNqM5kYfcXoFHsKAM6iiigAooooAKKKKAOi8B6pHo/iGK8c4dQQhzgAnvX1FqHieK58K3c8ckZZoh8quOu76V8dg4IIrrdB8T6kVntWnLI0ZOGGRkGgD1MahJN4bv5nkGEtpRyOpANFUrSOc/D+9mY/espnY/QMKKAPV/D5U/CCwDgEDQo1Yc/8+4z09q+Newr7M8LkP8NdLt2IAfSolJJ6ZhAr4z7UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUdqALkGp39vE0VvfXUUbdUSZlU/gDVy/168vtFs9OnlkaK3d3yzk7t2Ov0wfzrH9aXPtQA4GlyeM0z8KUdPagDoPC2sX9neQ21peXMCTOEAjmZACTjtX0hoFhOLKJbq6unmCje7ux5x2r5Tg4kTLbBkHcc8flX0p4E8ZaJNp8ds2sRTXCxpu3b1YsBz94DP4UAWtb8EyajcxSS6xdogGChdjnr+Xas6T4aFwPs0ilRwzMOW/8A15rvrLU9MmAHmJkDqzHA69KtrqVoYQsEylcckHvigDgbjwLa6TpEsttGnmIhPQlmOM8Z9/518763PJc6ncSTFixbkHNfWuo3EZtmkld9nUgEkkY5AA//AF15RrPgLS/FLzz6C11YXq7txu4HjjkOBjqMj8KAPET1/WkPJwRXZa38OPE+lPt/syW9T+/ZK0w/LAP6VgXPh/WbWMvdaRqMKL1MlrIoH5igDK7e9IKmaCUHmKQf8BNRMCDhgVPTB4oAaa6Xwd4Ym1q5Se4jkj0xT88mCN/+yp79OfSsfT9Nu7+dUtoJX6biFJAHqcV7joumXtpZWFu1uWjgiCEZOAcfy60Aa/gzRLCwKm3iXKgBME8LgfmfevQrSBXQMQpPqBgDjvXGadBcrKNzIpPRB0NdvpMQ8gZcnI9T6elAD3sot3zKGGOvOB71znjT7XJpV5BpRkjuWhcAoSpB28YPY5xXayRqqEcDg9fpVG7ijEMgVQQAfnPY0AfE11aXkU7rd29wk2TuEiMCT3zmqp6816V8VPGKXt5PpekTu9tHIyyTdA5BHC+2Qee9ebHJJJ60AJRRRQAUUUUAFFFFABXV/DDTG1nxlZ6eibxPlW/2V4JP5CuUr139mG0Fx8Rp5TjNvYSSL9S6L/JjQB7Z418PW1j4A14QghYdLudoB4OIm/z/AJ5K6L4iLu8AeJ8D5f7KvOpxjEL8UUAcTo4lfwNpdqN6mTT4dp57oABXyVgqSCCCOCDX15p8if8ACFaJKvIaxgxgY5KCvmj4h6cmneKLkREbJx5+0LgKWJyPzFAHNUUUUAFFFFABRRRQAUUUUAFFFFABQelFFACnrRSUtABS96SloAei7jwelekfCP4cav4u1GK82PaaNC6tLdOrDzBk5WP1PBBPQflXKeBfD03inxXpukwrIUuJl890TPlRZ+dz6AD+lfdGmWNvpmn2tpZxpDbQRrHDGowFUDAFAGAnw/0IWkcQt5GCAAN5r5OPxpT4B0cR4t1nhycgiRuuOp5rqlYgDO3p/dpUPyjC/dHGR/WgDjbXwt9hlbzpTPAcFCwORx3q7fWEXlFtmBg5AyCfpiumaMMm0j5TxjH614r8ZtX17QXjtbXyhps+SJth3KRjIJzQB1iw3EOsXEokjfTzGAkTAllYY5zn69afc2dvfkqwITOeM4Y564715Fp2q+I9W+yC5vESOTIATGdoA5PPevZ9OJigUIAzEA8jtmgDLj8PWcYaOC2WNWJyxGSefT/PaqsvgvSZ/Na4sLWRyc5aBck5+ldMj4TkBjknGO1RHLZPfHTt1oA8q17wJDYvNd6e0lusaAui5A796zNK8WaRqVvi0v8AY6IBJ5gK4OD0z1Hv7165NLBcQ4deB1V1+8B1z6j/ABr4+8XaE/hzxFcafK5MaNmKXbjch6Hr+H4UAe6aXLLJGtzC5niB2+YHJGccDrXYaLqE6sgnVlB/jOfTt7V8q6Nr17o90k1lKVCnOCMhuO4r0e2+LUr22b+xSUZCl4yVIFAH0O86CJnZhzk5Ge45rx745eM7y00iLT9MmaMXTFZpVyp2gDIBz781hj4h6S9rMTeTRsc/umhbnj1A615p4s1065fB0TZBH9wE5J9SaAMI880UUUAFFFFABRRRQAUUUUAFfR/7LHh5odP1TX5UZXuSLWBsH7inLEfVto/4DXzhX2Z8CrV7P4VeH4biMrK6yyY2ngNK7An0+Uj86AOi+IhVfh94oPO06Vdgf9+XH9aKqfFZ/L+HPiNicE2E46eqEf1ooA8W8IeIGm8LQaXNs3QRJ5Rx264rznxjBNqczTCP9/CdoVR94fn9a7LwBYw3uoLErDd5YOMDnivQZ/BFrfQlZgYJjJGiSLjO5mCqB6ncQPxoA+WKK7D4j+DLzwjqSLcKDBMAysGU8nPGAeOh646H0rj6ACiiigAooooAKKKKACiiigAooo7UAGMGlpPwpaACnD3pvoK1PDmmnVtatLPJVHkHmMOqpkZIoA+j/wBlzwx9i8N3XiCYI8mpSCOH5fmSONmU4P8AtMTkf7Ir3JRgjKgnjkd65X4Z2EWleC9KsIFYJChXkf7THJ9OvX1NdVjcCSGCnAOcev8An/PQAVVxjjoP0pQuMEKDnv3/AApU4HK+nGBx1pR15HfmgAKnaOORXL/EjRY9Z8NXcDxoZFjZlLL0OO35V1G3jofr+FVdYJXS7wqhYiF8DA5O2gD5u8CeH59E8WXguouFiwrY4OSORXttqQyBlUMuOMe5rxzSNefVtUlu7iRkgiLQSRnA2cjBHr3rrLvVX0tVS1cyochSQMjn1oA71mLuFVB1Pbt/SlWDcMvwR0xxiqejXAu7KGZs7nAJ6ZznFaSDnKAhSR2FAFO9sVaJmbCg4XJ46nAHPucV8z/HvTTaavpt02MyweWfXKk/419O6vfR2todx2kjhRjOc18afETxHL4n8TTXjsxhjUQwAgDCDP8AUn86ANLw7pXhO98FXc2q6hPaaxDKzqU2sXTaMIFJGcnPcGuG/ClxmkxxQAUU4sSFBxhRgYAH/wCum0APZwyKoiRSP4hnJ/XFMoooAKKKKACiiigAooooA0/DujXGu6pHZWuASNzseiqOp/WvuzTY4rayt4IVCRxoFVVAAAAHA9q+bvhX4el0zRWvJ4gl1djIbaCyx4BA9gete7+Drm4ubAPcLjBwvHTmgDI+ON0Lf4Y62D9+aLYueMgsMnH0orkPjzqhufC2pRKrCKJVVeOCS65ooA8w0HU4vD/iHT74FgkTKJAAP9WTz7V9DR6fp+p6pb63YNC13HCIRInlMwRmD4bIJGcKwPBAOR945+edW02N4v3m5H6gbsDrgjpXqHwP8YtfWB8OancIt1pyKlrvlGZost8oB/u8dOxzQB3mv6FYeJ9Jl03WbMXETqo80BVZGww3oTnDKCTz64718d+LfDmoeFdduNJ1WMLPFgq68pKh+66nuD+hyDggivuCOLE5kVz8ygY4wMZ5HHU5/QVj+NvCWneNdGXTNZMywrMJ43t3VZEcAjIJU8YY5BGD9QCAD4fore8a+F7/AMH6/LpOqmJ5lRJFlhJMcisM5UkAnHIPHUEdqwaACiiigAooooAKKKKACijNHbigBcc0UUvQZoAUD/6wr6c+CnwngstKtdb8QRzpqVxlltnwBEm75Sw67jgHGeAcdc1i/Av4Uyx3Fh4o8RbEVR51nZk4dWDEB5FK/QgD1B9q+iUO5m3EFee/HWgBLSEW0ZjUBUGABgeverPykgnr696q6dexXiObYgpG5j7dQe3+e9Gp38Om2T3Ny4SNAMknHU+tAFwHp3yMcY4oztcfMoz2OPb/AOvXDz+O4M/uQCFwDhs846UzSvHZluNl1bERbseYD09jQB3ijjBGT9B6VDexpLbTRyHEbIytyB8pHNFvMs0KPGQyMM5B68VMRnJ4GM9/5UAeL+LfAVv4f03WbvTUkktLmJmlUkfu+Mkj2rx/RPEMVrNHZa40htVOIZUx8nI6+1fYV7Cl5bT283MUyMhB7qRg9R718Z+KNLOieL7/AEi5j3W8E7JHv+8UzlWzj0xQB7Z4Fnil1OKSLUYJLRkOzyir55HB9K9Hu5bSKzJhuUYjBC7hyM8+/wBK+cfD4tdIMc2nzSKpz0bJq/qviK4uJsRyeS/3d5bORnvQBr/E3xONP0a5drhPtjoFhU7cnJA4HfAJr5u47V0njzUxqetgxyvJHBGIsnpnOTiubzz1oASiiigAooooAKKKKACiiigAooooAKsae0S6hatcKXhEql1HVlyMiq9d18GvCi+LPGUdvMXWC2j+0synH3WUYOQf71AH0t4b0wakRNNHsskUEKoA3Nxxj0xXZLBGE2IoVB2A4/CnWtvHaW6xRgBEGBjmq2uXy6Vpc1xIykIPly3OS3/16APCfjrKG0nVkV8qpQKAR2lSiuY+J+pm50q+Ziv+kBcfNk58xSf5UUAdv418M3ttbzXUUSkFs+VHL5gX5j/EVGeMckL9K8f1L7foOq2ur6dI0M8TCWOQqDhh2IPBHqDwc19GaF4tt5o0t9TIRgMCQ5KyfX0/lWP42+G9v4hsmbSilpOTuCu7GNuevAPUelAHSfDTxvaeM9DSeFkS9hCrd227mNvUccqeSD+HauqknMJDYyvY8YH5f55r5E/srxX8P9cjvoLe5sbmH7s3lsYpV7qTjaynHQ1798O/ibpPi2KCxu8WOuP8rWcmSJMKCWRsYI68Z3DB69SATfF3RrDxV4TmtrqQR3EDGe2fcAUcLgZ45U55H+FfIl3byWtzJBMMSIcH396+pPiRaXcMRa33Op4IDkEDHWvA9W06aWaeO7WTeoLRSSBs5PQE+lAHJUU+WKSJiJEZcHGSODTKACiiigAooooAKUV13g74deJfFcsP9nadLFZykgXtyrRwDjP3sHP/AAEHqK9r8EfAPS9PDT+MJxqkuDi3t5HigHHUt8rt/wCO0AfPXhzQdT8Saoun6HZy3l2w3bI+iLkDcx6KoJHJ45r6S+F/wUs/D839oeKjbajqqEmGCNi9vF90hiGUFnBB6/Lz0PBr1fSNNsNKslstGtILOzU7hFboFUnAGcDqcAc1dVVj3kBySOSMkmgDlvHniDQ9AXT7/Wr10ntpWmtoIpfnlJUoQVHVcPnsMgelZXhrxrN45v5rLS7WW0sYUzLcu2dwJAKrwMHn+dUfHHhqxu9ei1LyBdX6HB3szYXIwMdAB/nNdn4WMkVpDA0QjRFxtUHA59KANrTrSKxtY7eBQsagkc8k57/nXN/E0yL4dZ1UPGrr5mTnuAP1xXVk84JPXp+NNmRJ4Ckiho2XDA5IIoA+brW5LGNyqRw9QoIHJJJPA7nNb8F/FKVRyH6cqfauT8beHrzw5dnzm/0bqJkDYzzxkjGeK1/hlpk2uX9sJ1m+w4y0p3KGwOx7nNAHtfgSZp/Dtu5bABIGT2q/r1tqkrW8mlXyQNG5aWKRQRKOMjOMg8Vds4I7W2jhgTy4UXCqueBirG/duIOR3NAEaOZVJOFcD5lDZx0rz/4r+A08VWkF9ZrnVrNSIhkATKWUlWJHbBx9ayfjX4n1LwheaTqukMxaXzIpYmPyOABjcPzHFdp4G8U2fi/w5aavZIYRNuEkBfJiZWwVP5ZB9KAPmf7QtvdeRcwvbzRtskRzypBwQe1R3cHznys7Nw43dfQCvZvjN8OT4ji/tbQURNXiJM6lm/0lPTHQMO3Azkj0rwsXl1YagLbUo54Xi/dtFICpQjPBB79aAOM16wa2undUdUPJ3djWUfwr2y1tLK/t3FzJ5kTgBhzlv84rFv8AwLo890PsdxLbpjlclvX8aAPLBRXoUPw6lmt38u5C3GfkEisqnj1xXP33g7WbKLdJbh8EgiMljwOuMUAc7RTpI3ikKSKVcdQRg02gAooooAKKKKACilVWY4UE1bt7JywaRCydcDPNAFzw3oF5r19FDaxuY3fYZAOAfT619jfDjwba+DtFNrblXuJCWlkB74A2g+nFeffs/eFPsdius3sLxSSZNrEQw2rjDOeMZOePzr2tX++BnA7nODQApkDo2yTcFypPHUcEYxXi/wARPFD+IdYOl6XKDaWUjLMyuCsr5HfHbB6Vs/F3x1/Z0c3h/RZA2sXMTLM+SPssZUYYnH3jnj0/KuX8NeD7oeHNsCyLEwJ3EEFxkkkZ60AeR+Jxd6jDqQhANrpkfmy4HHMscfb3cfrRXuPxD0Kx8MfBLX7OGFUmmjgLtklmP2uFjn8sflRQBz0NsrqGBGSACTnH0rpPD2vXelSeVLumhIUBJJWOwDj5eOM+lcxbttAE0qyMRtzsx+lJduEjUrk7QMbEPJ/l+ZoA9etdQ0zW7N0TyJ12fPDLzgkdwR05rwr4mfD06LNBrXh0yw2T7CiAvHLbttJJOeR0z2IJxxVlprgT5T90+OXzh2HPAKnjPrnv2qSXVdUu7U219cST22dpDFienXJoAx/C3iXX7uJdO1aSe9TJIuJXLv04BY9R7mvVfDuiwTwMdSsUkcE4YDIxxXnXh0x6VqaTZEgXIKHOSMda9z8PX9nqdsZLSRXAO0ryCpGOMH8KAMLVfhh4V1i1ZTpot3IOGiJBz64/wryvXv2e9SS4LaFrFlLCcny7wPEw54AKhge/XHSvo5AMDA/U46fX/OKk9OTgf40AfHeqfB/xtYRtINI+1Rqf+XWZJG/BQdx/KsC48E+KrdWafw1rUaL1ZrGQAfjtr7hfCg7jxnPQ5rD1uSW5haGNXCSDHAPHP/1qAPh5oHR9j4V842nrXtHwk+GFvdSRap4itlvY2VXhtNxCDIzmT17cdPXPSjVfhsdO1Bp7dZTHw4baTj3zmun8P6lfaUkf+kO8QA7e1AHtWnwLHbRxRIkKRKqKkagKqhQAoHQADtVvb8pwAcdvwrza38Z3jBHUoIyBwVJzx61neIPEWp3kJWC5ltScBQgOOnQd80Adr4x8baJ4ShMmqXYWV0YxQIGZ5CB0wAcdhk8c1kaN8RrfW9OWe2tXgaU7QsjE4HGOce/avAvFui6pdXr3EpuLxv4nJJPb1PtXt3wr0azm8NW8tzAyzKSCCxyMAe/HegDqIIbt5Gd4YpJGzyWOCevPGcf4Vo3l3Bpdr507CIDPyg9T6VkeNvFNt4V05X2h53yFQgkcEDJ/OvFfF19q3jGa2eaeRInJ2LFnaMkdfp70AdnrXxRNjqu9rgRRKcmBtzBhnvgcZ5r0zwd4p03xXpK3+lTiRAAsqchom/unIHp1718+Q+D7OO3SO7gkuZWGGd5GBXnOeDUvhzTNV8Ea9a6jol9K1lLNGt5AU+SSPdgg8nkAkg9qAPpC/wBIsNQiMV5aRTxNgFXXNFlpNjZ7Ba2sUQTACouAPw6VMkxkZfJzsIyZCpx3GB05yPp+PFcZ428TX1mUs9CMKzZHmTzKWVOOijPXOOucUAdHrviPTtEQf2hOUZuRGoZicD0AzWHb/EDTb6ZorRZG4OGfKj+VeQapo2uNeG/m1SW9l6lSp9Pc1egtw45Miz5OFVcEnr6+x60AXPiah14u91M7CMMwRJOF49DWL8AtU/sbxjdaZLPMtreoVWNidomB4OOmSMiu0udLsry2MVyR5zxn93gjJx0zXgniX7XomvPLbu0DxTloGBztKtkH8KAPtGWRkbIBZSefXrXIeNfAmleLIZZnt1g1PaFjuRnsScMo4PU+/NZXwu+Itt4q0q2gv54l1sIxmjRWAIDYDDPrkcA969F27s84OOPf/P8ASgD5S1nRdb8Eakker27x2uVxcRb3hYezY689Dg1ZjnSeZJ7e7EucHKgjr9cV9M6pZw39k9pewie0lADxtnnHI6HPbtXhPxH+Hl1oCJqHhmGW8ssgSWiqWZRg5brkjjrQBjm6cxAPI6sDgfMSSMfyqg15LDKjrJcEc7gEJ7cmsa21OG4jXZC3mg/OiscjjtmrQnU7SrTLx1OT2oAvTeG9G8RXM0lxZz21wy486PPJwB93p6Vz+p/CjWbdDJZyRXCEkouGUkDHXIwDyOM/yrsdKuo0Y4kZXI3feIz+tdJDds0Q3SOw6H5u9AHgVz4T123Te2m3Dp13Rru4/Cqn9iairYltZIu5MikYr32+kJYOrYTJGM9TWdNpkF2pYMd3IKqDz+NAHjaaBNIhKTIzDnaFPIqydGSBolljdmwC2c8nPSvWbTw1NK6iDKgNyApbB56YPrW5a/Du7mYPPAZWO3BkBjH5ZoA8estPN3FhoDEi/wARXaBWlaacghLxQ7whwWJwDivXJvh9LKiLd3AKp0jjT5fxOaxNas7DQUiXUHUQq4ymCO3sc0Aei/D25luPD1lGiSRxIgBJYnoKxfix8UrLwsJ9H0tTd666MhVGKi1Zk+R24O5vmBCjnjkjv55rnxR1S8sn0jwZZNaWpXabtQxlGRzt/u/U8+mK0vhXoOk6HeTa34ima91V2Ji8xWYoeCWzk5bIPJoAt/C34f6rqV3Pr3jVLljcAnyruRzcTN8uGfuFx2znjoK9ovp7axtl3oAMYVU+XOD29OtcVe+OZJ70QaeiBBkNK6nOP0xQ+oSXB3ySbmbqWJx196AOc+MF7Lc+A/ELynG6OEqueQPtMP8A9aiq3xTP/Fu/EJPJ8qEd/wDn5hooA5Ow1Pz1WNDgg9dmT3x1q3cX7IItzYyBglcZB7/SvK7DxPNboQ8as3ZwOR+taY8YxyKiTI+FxyUBI+nNAHa28j3UsjB03dABuByM/WtCzSZgFOBuAO7JCnjpxXn8PiuyWYPunjwMEhetbVp410jYommYOD1MLEYx6CgDqHSdTuQKgOCfkzzirlhdX+n3QmtrhEc55aMjBxnnB9sVy8fjLQ3BLX/lMOg8h/6L/h1qz/wm3h8bWW+TJBU7reQ7fp8vtQB7DoHjqGT91rYjt7gcBo0Ow/zIrtbe6iuYkktpEkTOdy9CM4r5uTxv4cYt5upgYJKkW8hP/oNX4PiJoFuALfWniYZ+dIJQev8Au+lAH0OcMcYz+Gc/5/wqje3thYITdyogHO0jLdeyjn9K+bNS8caTcyO51q6mbkgSCUj8Bis3RPFllaSTEak0crsMHynY46+nvQB6r4o8W3+o3LW+j2KCxCj97MjK7/7uOAK5fSo79rkCYFN3T9ycCqsfjbRAVcXzv0OPJfr7cUmoeLNNn05Bp107zHhUZGGcZ7kY7UAdXaRlYFVgsmOp2n5veo2gf78iqRjrznpjp+Fc94W8SxSqiXjpHJjPyqxPQf411UNxZ3KB4WEmG7qR2x0oAoJA6sfLTzM5BI5A/E9+tYfiMTaZcrcq8yxyDDqrYA49PyrrLu6tIQMjyzjO5Vzjt0qpfaZa6k5eQloSuBkZ9OmaAIfDjR39km4QyuDhlcbiMHgc8+tbE4t7aaNHIiDDC4Tvnpj06c+/58ldaBPpjtc6ZhTuwytgbiMc8Hg96gj8TyLqtrZzQx75HxvK5wM//roA6VrW5S7LQ+YY933gnTnvWjpGmw3d9Bb3W9pHlQemQDz+lWIFD2+7YuzAwQMHrVq2WO0kN0EUCFlccZyR6/lQB6fGiQwLFHwFTCjHYAivKNat2dYjDPJG4bIOM7uvFOs/i3pWtahFpditxDM/3mZOGwOQP/r1oymKQliuRnP3R/jQBzljb3TS4n81lY54Tg8e/wCdbLwJGjkoAuCd3p0rNv551gmEiBUx8rKeen1p0V4g08zSTGZNhJyvB79DQBehgTZmWX95jOdn3f8AP+cV438RtOvJ9ZRYoIijuxQryW5HJFev2t0kwYKpBYZz+XSqr6RBdXauwQ+WSQSgJ+gPagDyDRfCOu28yXcVthV5GM54PtXr3gjxVrFgptr+2kES4AZlYgNz0OfpS3FsjYhVAPbjBGams7dhEyMhZTzw3v70Aehab4gtriNDM6KSADgHBPfHNWL1omiLRkbT7ZzmvOIHaIr+5G0E5zgnOfrSDVJ47ryjGwiA3O24ED8KAON8eeBbfUNTluLLy7aRm3ERx4U/h61wDafq2mzR2mo2DSW4OBKiE9uu4V7NqN7j53nRkBGQyEk1f8F3+ha5M1ou5byMnKPFw3HJB6etAGT4Z+GunXtojTXUsbk5wv0FdXF8MdLU5FzcnAwcEY+vSultdGFqXNsBtYEbSBir8ck8bAOM54JGOP8APT8aAOQb4Z6O6oGlvTtOciQAn9K2tM8I6PpsarHZRyN3eVd5PPfPFdCCcKcZBOMY96ANzDjnPYds/WgCrBaW9uD5UMMQ4ztjAxUjx7h0HTutS4wCTjBOee1Zuqava6YmblmJOAEVfvfjQBLLGkaF5Qq7fmII/KvCfHWiHxL4gM1xJi1Q4WJExx9c122s6292ixiCKG1UH92i4Bzk8/mTx6msSWTdtVI42HdelAGDaWEVhEsVtaRxoh2grHjt6+vNTX0vlwYES45H3OcYrTEUcpOUBKHnHGOKzdfjCI4+TJXgEdaAKE07QqREpOc5byzk8f8A6q6PR5wtsgc8cgZz615uHvp7kRxRBYI85O4cn866mzd0ijD4Qnqdobv9aAF+J13CPAWsxB1BdYlQHjcfPjPf2BP60VyHxT1ON9BitopSWadSyhSMjDHn2zj9KKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Malignant, amorphous calcification in a left upper lobe bronchogenic carcinoma with metastatic disease to the left hilar lymph nodes and an accompanying small left pleural effusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_34_3616=[""].join("\n");
var outline_f3_34_3616=null;
var title_f3_34_3617="Brown recluse spider bite";
var content_f3_34_3617=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Verified bite of brown recluse spider (Loxosceles reclusa)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from&nbsp;William Stoecker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_34_3617=[""].join("\n");
var outline_f3_34_3617=null;
var title_f3_34_3618="Patient information: Newborn conjunctivitis (The Basics)";
var content_f3_34_3618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/52/23362\">",
"         Patient information: Chlamydia and gonorrhea (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/25/21906\">",
"         Patient information: Genital herpes (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/14/24802\">",
"         Patient information: Chlamydia (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/51/20274\">",
"         Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/44/1730\">",
"         Patient information: Gonorrhea (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Newborn conjunctivitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/newborn-conjunctivitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13926569\">",
"      <span class=\"h1\">",
"       What is newborn conjunctivitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Newborn conjunctivitis is a condition that causes eyelid swelling, eye redness, and other symptoms in newborn babies.",
"     </p>",
"     <p>",
"      In the United States, newborn conjunctivitis is usually caused by an infection the mother caught during sex. The most common infections that cause it are chlamydia, gonorrhea, and herpes. Many women get tested for these infections before giving birth, but not all do. The baby is more likely to get the infection if he or she is born through the mother&rsquo;s vagina. But babies born by Cesarean section can get newborn conjunctivitis too. A Cesarean section (also called &ldquo;C-section&rdquo;) is surgery to deliver the baby.",
"     </p>",
"     <p>",
"      A few other types of infections can cause newborn conjunctivitis. These infections are not caught during sex.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13926584\">",
"      <span class=\"h1\">",
"       What are the symptoms of newborn conjunctivitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of newborn conjunctivitis usually happen 2 days to 6 weeks after birth. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Watery liquid from the eyes &ndash; This is not the same as normal tears. &nbsp;",
"       </li>",
"       <li>",
"        Thick, gooey liquid that comes from the eyes",
"       </li>",
"       <li>",
"        Eyelid swelling",
"       </li>",
"       <li>",
"        Red eyes",
"       </li>",
"       <li>",
"        Crying and acting like the eye hurts",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Antibiotic medicine is placed in the eyes of most newborn babies in the United States soon after birth. This helps prevent conjunctivitis caused by gonorrhea. It does not prevent conjunctivitis from other infections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13926598\">",
"      <span class=\"h1\">",
"       Should I take my baby to the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if your baby has symptoms of newborn conjunctivitis. If it is not treated, it can cause serious eye problems and blindness. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13926613\">",
"      <span class=\"h1\">",
"       Will my baby need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will ask about the baby&rsquo;s symptoms and do an exam. He or she will do tests to look for the cause of newborn conjunctivitis.",
"     </p>",
"     <p>",
"      Tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Tests on a sample of liquid from the eyes",
"       </li>",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        A lumbar puncture (sometimes called a &ldquo;spinal tap&rdquo;) &ndash; During this procedure, a doctor puts a thin needle into the lower back and takes out a small amount of spinal fluid. Spinal fluid is the fluid that surrounds the brain and spinal cord. He or she will do lab tests on the spinal fluid.",
"       </li>",
"       <li>",
"        Tests on a small sample of cells from the eye, throat, or rectum, or a sample of a bowel movement",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13926630\">",
"      <span class=\"h1\">",
"       How is newborn conjunctivitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Newborn conjunctivitis is treated with medicine. This can be:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antibiotics to fight bacteria &ndash; The baby might get these medicines by mouth, as a shot, or through an &ldquo;IV&rdquo; (a thin tube into a vein). The type of antibiotic depends on what kind of infection is causing the conjunctivitis.",
"       </li>",
"       <li>",
"        Medicine to fight infection from a virus &ndash; This is called &ldquo;antiviral medicine.&rdquo; Doctors give this for newborn conjunctivitis caused by the herpes virus.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some babies get treatment in the hospital for newborn conjunctivitis. This could happen if the conjunctivitis could cause other eye problems or spread to other parts of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13926645\">",
"      <span class=\"h1\">",
"       Can newborn conjunctivitis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are good ways to prevent newborn conjunctivitis. You can do the following things:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        See a doctor or nurse before getting pregnant, or as soon as you get pregnant. He or she can check for infections that could cause newborn conjunctivitis. You can get treatment before you give birth. This can keep the baby from getting conjunctivitis.",
"       </li>",
"       <li>",
"        Check to make sure your baby gets eye antibiotics right after birth. This is part of routine newborn care in the United States. The antibiotics can lower the risk of infection with gonorrhea. This infection is 1 cause of newborn conjunctivitis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13926660\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=see_link\">",
"       Patient information: Chlamydia and gonorrhea (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=see_link\">",
"       Patient information: Genital herpes (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=see_link\">",
"       Patient information: Chlamydia (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=see_link\">",
"       Patient information: Gonorrhea (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/51/20274?source=see_link\">",
"       Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?3/34/3618?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83759 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-C2273CD5CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_34_3618=[""].join("\n");
var outline_f3_34_3618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13926569\">",
"      What is newborn conjunctivitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13926584\">",
"      What are the symptoms of newborn conjunctivitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13926598\">",
"      Should I take my baby to the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13926613\">",
"      Will my baby need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13926630\">",
"      How is newborn conjunctivitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13926645\">",
"      Can newborn conjunctivitis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13926660\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=related_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=related_link\">",
"      Patient information: Chlamydia and gonorrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/51/20274?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=related_link\">",
"      Patient information: Genital herpes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=related_link\">",
"      Patient information: Gonorrhea (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_34_3619="Sonogram abn ut bleeding3";
var content_f3_34_3619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transvaginal pelvic sonogram of a patient with abnormal uterine bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The central uterine echo measures 9 mm and appears relatively homogeneous.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_34_3619=[""].join("\n");
var outline_f3_34_3619=null;
var title_f3_34_3620="Epinephrine (adrenaline) (nasal): Drug information";
var content_f3_34_3620=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Epinephrine (adrenaline) (nasal): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/59/4020?source=see_link\">",
"    see \"Epinephrine (adrenaline) (nasal): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/14/40163?source=see_link\">",
"    see \"Epinephrine (adrenaline) (nasal): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8084972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenalin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8090006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenalin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8090008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-/Beta- Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8114287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Decongestant:",
"     </b>",
"     <i>",
"      Intranasal:",
"     </i>",
"     Apply",
"     <b>",
"      1:1000",
"     </b>",
"     (1 mg/mL) solution locally as drops or spray or with sterile swab",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8114286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/14/40163?source=see_link\">",
"      see \"Epinephrine (adrenaline) (nasal): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Decongestant:",
"     </b>",
"     Children &ge;6 years: Refer to adult dosing",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8114288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8085184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as hydrochloride [drops/spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adrenalin&reg;: 1 mg/mL (30 mL) [contains chlorobutanol, sodium bisulfite; 1:1000]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8084991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8084992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of nasal congestion",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8084970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       EPINEPHrine may be confused with ePHEDrine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8085027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, cardiac arrhythmia, chest pain, flushing, hypertension, pallor, palpitation, sudden death, tachycardia (parenteral), vasoconstriction, ventricular ectopy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety (transient), apprehensiveness, cerebral hemorrhage, dizziness, headache, insomnia, lightheadedness, nervousness, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dry throat, loss of appetite, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Acute urinary retention in patients with bladder outflow obstruction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Allergic lid reaction, burning, eye pain, ocular irritation, precipitation of or exacerbation of narrow-angle glaucoma, transient stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8085000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular diseases (eg, coronary artery disease, hypertension).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular disease: Use with caution in patients with cerebrovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may transiently increase blood glucose levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease; may cause temporary worsening of symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Use with caution in patients with thyroid disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tricyclic antidepressants: Use with caution in patients taking tricyclic antidepressants; effects of epinephrine may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of COMT",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8085030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of EPINEPHrine (Nasal).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Promethazine: May diminish the vasoconstricting effect of EPINEPHrine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8084996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to the EPINEPHrine (Systemic) monograph.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9890220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to the EPINEPHrine (Systemic) monograph.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8085186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Adrenalin Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (30 mL): $50.42",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8090023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8090015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates alpha-, beta",
"     <sub>",
"      1",
"     </sub>",
"     -, and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors resulting in local vasoconstriction and relief of nasal congestion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8090017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Taken up into the adrenergic neuron and metabolized by monoamine oxidase and catechol-o-methyltransferase; circulating drug hepatically metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as inactive metabolites, metanephrine, and sulfate and hydroxy derivatives of mandelic acid, small amounts as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9115 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-189.41.172.26-83C8AEB15F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_34_3620=[""].join("\n");
var outline_f3_34_3620=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084972\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090006\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090008\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8114287\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8114286\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8114288\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085184\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084991\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084992\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084970\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085027\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085000\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299270\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085030\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084996\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9890220\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085186\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090023\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090015\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090017\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9115\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9115|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/59/4020?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/14/40163?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/4/11337?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/24/10630?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/20/10568?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_34_3621="Klebsiella pneumoniae liver abscess";
var content_f3_34_3621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Klebsiella pneumoniae liver abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography (CT) of a primary liver abscess due to Klebsiella pneumoniae. The multiloculated appearance can make radiographic distinction from a hepatic tumor difficult. In such cases, diffusion-weighted magnetic resonance imaging may be helpful to better differentiate between abscess and tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Wen-Liang Yu, MD and Yin-Ching Chuang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_34_3621=[""].join("\n");
var outline_f3_34_3621=null;
var title_f3_34_3622="Small cell ca CT";
var content_f3_34_3622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest CT scan from a 66-year-old man showing a bulky central mass with adenopathy confirmed by bronchoscopic needle biopsy as small cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_34_3622=[""].join("\n");
var outline_f3_34_3622=null;
var title_f3_34_3623="Somatostatinoma";
var content_f3_34_3623=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Somatostatinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/34/3623/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/34/3623/contributors\">",
"     Stephen E Goldfinger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/34/3623/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/34/3623/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/34/3623/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/34/3623/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/34/3623/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/34/3623/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatinomas are rare neuroendocrine tumors of D cell origin that contain and sometimes secrete excessive amounts of somatostatin (",
"    <a class=\"graphic graphic_figure graphicRef80502 \" href=\"UTD.htm?20/60/21447\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/1\">",
"     1",
"    </a>",
"    ]. Somatostatin is a tetradecapeptide that normally acts in a paracrine manner to inhibit secretion of many hormones, including insulin, glucagon, gastrin, and growth hormone. It also has direct effects on a number of gastrointestinal functions; for example, it inhibits cholecystokinin-stimulated pancreatic enzyme secretion and gallbladder contraction, intestinal amino acid absorption, and gastric acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/2\">",
"     2",
"    </a>",
"    ]. It also diminishes gut motility, thereby prolonging intestinal transit time [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/29/4567?source=see_link\">",
"     \"Physiology of somatostatin and its analogues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency with which somatostatinomas secrete somatostatin varies. Some somatostatinomas, particularly those arising in the ampullary and periampullary area, contain immunoreactive granules but are not associated with any functional syndrome. On the other hand, those arising in the pancreas may secrete somatostatin, resulting in a constellation of symptoms known as the somatostatinoma syndrome (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical manifestations'",
"    </a>",
"    below). Only about 10 percent of patients with somatostatinomas experience somatostatinoma syndrome.",
"   </p>",
"   <p>",
"    The mean age at diagnosis of somatostatinomas is 50 years (range 26 to 84), with a roughly equal distribution between men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/3\">",
"     3",
"    </a>",
"    ]. Approximately one-half of these tumors are in the pancreas, two-thirds of which arise within the head of the gland. The remainder arise largely in the duodenum, particularly in the ampullary and periampullary area [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/4\">",
"     4",
"    </a>",
"    ]. Rare primary sites include the liver, colon, and rectum [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. The majority of the tumors are malignant. Those arising in the duodenum often contain psammoma bodies, which are structures that microscopically look like hardened concentric rings [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The origin of psammoma bodies is controversial, but one theory is that the nidus for their formation is a single necrotic tumor cell, upon which layers upon layers of calcium salt deposits are added.",
"   </p>",
"   <p>",
"    In contrast to its pancreatic counterpart, the duodenal somatostatinoma is frequently associated with Von Recklinghausen's disease, is seldom associated with a recognizable \"somatostatin syndrome,\" and is less frequently associated with demonstrable metastases at surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. Somatostatinomas have also been reported in the MEN-1 syndrome; these do not tend to metastasize [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptoms in patients with somatostatinomas are abdominal pain and weight loss.",
"   </p>",
"   <p>",
"    Tumors localized within the pancreas sometimes cause the three classic findings of the somatostatinoma syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Cholelithiasis",
"     </li>",
"     <li>",
"      Diarrhea with steatorrhea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These symptoms result from the physiologic actions of somatostatin. Diabetes results from inhibition of insulin release [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/2\">",
"     2",
"    </a>",
"    ]. Cholelithiasis is thought to be a consequence of decreased cholecystokinin release, which reduces gallbladder contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/9\">",
"     9",
"    </a>",
"    ]. The diarrhea and steatorrhea are probably caused by inhibition of pancreatic enzyme and bicarbonate secretion and inhibition of intestinal absorption of lipids [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/2\">",
"     2",
"    </a>",
"    ]. Many patients with somatostatinomas also have gastric hypochlorhydria due to decreased gastrin secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, patients with duodenal somatostatinomas rarely present with the classic syndrome. Their most prominent symptoms are usually caused by local mass effects rather than the actions of the hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. Abdominal pain and jaundice are common presentations. It is unclear why duodenal somatostatinomas rarely cause the somatostatinoma syndrome; one possibility is that they do not produce sufficient hormone quantity to cause a systemic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS, LOCALIZATION, AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;While occasionally encountered first at laparotomy, somatostatinomas are usually detected as pancreatic or duodenal masses in the course of evaluating patients with abdominal pain, jaundice,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weight loss. Given that 75 percent of somatostatinomas have metastasized, often to the liver, at the time of diagnosis, presenting symptoms associated with the tumor may also be related to extrapancreatic and extraduodenal masses.",
"   </p>",
"   <p>",
"    If a somatostatinoma is suspected preoperatively on the basis of the classical triad of diabetes, gallstones, and steatorrhea with or without the finding of a pancreatic or duodenal mass on radiographic studies, a fasting plasma somatostatin level should be measured. A concentration exceeding 160",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    is suggestive of the diagnosis. Mild elevations sometimes occur in other endocrine disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H390421\">",
"    <span class=\"h2\">",
"     Localization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laboratory abnormalities suggesting the presence of somatostatinoma should be followed by attempts to localize the tumor. Cross sectional imaging with helical, triple phase CT, or MRI is the initial procedure of choice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145107#H12145107\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Computed tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the primary tumor is usually large by the time of diagnosis, it is localizable by CT in the majority of cases. Intravenous contrast enhances the detection of smaller lesions, especially when images are obtained during the arterial phase. In addition, arterial phase and portal venous phase sequences can be used to maximize the conspicuity of liver metastases compared to the surrounding normal liver parenchyma.",
"   </p>",
"   <p>",
"    As a result of its greater sensitivity for liver metastases, some physicians prefer MRI over CT for assessing the status of the liver. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145107#H12145107\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Computed tomography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145114#H12145114\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the primary tumor is not visualized on cross sectional imaging, endoscopic ultrasound (EUS) is the next diagnostic procedure of choice. EUS can detect pancreatic tumors as small as 2 to 3 mm, provides accurate information on the local extent of disease, and allows transmucosal needle biopsy of pancreatic lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145121#H12145121\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Endoscopic ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Somatostatin receptor scintigraphy (SRS) using radiolabeled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    is very sensitive for pancreatic neuroendocrine tumors, including somatostatinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/6\">",
"     6",
"    </a>",
"    ]. However, technological advancements in CT and MRI over the past several decades have led to diminished utility of SRS as a component of the staging workup, particularly for somatostatinomas, since they are usually large by the time of diagnosis, and easily visualized on cross sectional imaging.",
"    <br/>",
"    <br/>",
"    However, SRS can identify clinically unsuspected extraabdominal metastases, and there may still be a role for SRS in the evaluation of a patient with somatostatinoma if the finding of extraabdominal metastases would change patient management and the treatment plan. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145128#H12145128\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Somatostatin-receptor scintigraphy (OctreoScan)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    FDG-PET imaging has also been reported to be useful in detecting a malignant somatostatinoma, although its place in the diagnostic evaluation is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic endocrine tumors such as somatostatinomas are included in the combined American Joint Committee on Cancer",
"    <span class=\"nowrap\">",
"     (AJCC)/International",
"    </span>",
"    Union Against Cancer (UICC) TNM (tumor-node-metastasis) staging system for pancreatic tumors (",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"UTD.htm?42/32/43532\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/12\">",
"     12",
"    </a>",
"    ]. Five- and ten-year survival rates for patients undergoing resection for a gastroenteropancreatic neuroendocrine tumor (both pancreatic neuroendocrine and carcinoid tumors) stratified by stage at presentation are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef80523 \" href=\"UTD.htm?4/42/4780\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other neuroendocrine tumors, surgical resection is the treatment of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/9\">",
"     9",
"    </a>",
"    ]. However, because 75 percent of patients have tumors that have metastasized by the time the diagnosis is made, curative surgery is often not possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Radiation therapy for nonsurgical candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with external beam radiotherapy (RT) in the management of pancreatic neuroendocrine tumors is limited. Although pancreatic neuroendocrine carcinomas were previously considered to be radioresistant, data from published case reports and small case series suggest that RT can produce high rates of symptom palliation and freedom from local progression in patients who are not candidates for surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment options for metastatic disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23750494\">",
"    <span class=\"h3\">",
"     Octreotide and interferon alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The somatostatin analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    inhibits hormone secretion of various neuroendocrine tumors. It is the first-line therapy for symptomatic disease in patients with unresectable tumors. Octreotide is associated with objective tumor regression in fewer than 5 percent of cases.",
"   </p>",
"   <p>",
"    Therapy is initiated with 50 to 100 &micro;g subcutaneously three times a day and the dose is increased gradually as needed to control symptoms to a maximum dose of 500 &micro;g three times a day. Long-acting forms of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948921#H190948921\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Somatostatin analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interferon alfa (IFNa) improves symptoms of hormonal hypersecretion in 40 to 50 percent of patients with pancreatic neuroendocrine tumors, induces tumor stabilization in 20 to 40 percent, and provides objective tumor regression in about 15 percent of patients. The addition of IFNa to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    has also been effective in controlling symptoms in patients who are resistant or refractory to octreotide alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948949#H190948949\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Interferon'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of three patients with somatostatinomas,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    injections (500 micrograms daily) improved diarrhea, diabetes, and weight loss for at least six months in two patients with the somatostatinoma syndrome, and remained improved at one year evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, in all three patients, octreotide therapy was effective in progressively decreasing plasma somatostatin levels by 40 to 80 percent after one year [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23750312\">",
"    <span class=\"h3\">",
"     Liver-directed therapy for metastatic disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23750320\">",
"    <span class=\"h4\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common site of metastatic spread of somatostatinoma is the liver. Although the majority of cases will not be cured, debulking surgery can provide symptomatic relief [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/18\">",
"     18",
"    </a>",
"    ], and extended survival may result, given the slow-growing nature of the tumor.",
"   </p>",
"   <p>",
"    As a general rule, resection should be undertaken only in patients with a limited number of hepatic metastases and is most successful when undertaken with curative intent. There is some risk to noncurative surgery since it appears to be associated with an increased incidence of local surgical complications, possibly due to poor wound healing related to the continued catabolic state.",
"   </p>",
"   <p>",
"    Concomitant resection of the primary is indicated if the primary site is causing symptoms, or if both the primary site and liver metastases are amenable to potentially curative resection. Contraindications to surgical treatment for metastatic liver disease include diffuse bilobar involvement, compromised liver function, or extensive extrahepatic metastases (eg, pulmonary, peritoneal). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691406#H691406\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postoperative complications include rebound gastric acid hypersecretion and intravascular fluid overload resulting from a shift of copious amounts of fluid from the intestinal lumen. Proton pump inhibitors and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    are recommended in the preoperative and perioperative period to prevent these complications [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23750327\">",
"    <span class=\"h4\">",
"     Hepatic artery embolization and chemoembolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver metastases derive most of their blood supply from the hepatic artery, whereas healthy hepatocytes derive most of their blood supply from the portal vein. This provides the rationale for therapeutic embolization of the hepatic artery, with the goal of inducing necrosis of the metastases with minimal damage to normal liver parenchyma.",
"   </p>",
"   <p>",
"    Hepatic arterial embolization with or without selective hepatic artery infusion of chemotherapy is frequently applied as a palliative technique in patients with symptomatic hepatic metastases who are not candidates for surgical resection. Response rates, as measured by a decrease in hormonal secretion or by radiographic regression, are generally over 50 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691449#H691449\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Hepatic artery embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23750334\">",
"    <span class=\"h4\">",
"     RFA and cryoablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other approaches to the treatment of hepatic-predominant disease include radiofrequency ablation (RFA) and cryoablation, either alone or in conjunction with surgical debulking [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/21\">",
"     21",
"    </a>",
"    ]. These procedures, which can be performed using percutaneous or laparoscopic approaches, appear to be less invasive than either hepatic resection or hepatic artery embolization. However, both techniques are applicable only to smaller lesions and their long-term efficacy is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691456#H691456\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'RFA and cryoablation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23750341\">",
"    <span class=\"h4\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of patients with liver-isolated metastatic pancreatic neuroendocrine tumors in whom orthotopic liver transplantation (OLT) has been attempted is small and follow-up data are insufficient to judge whether complete cure has truly been achieved. The limited availability of donor organs in many regions has restricted investigation of this procedure. Until more data become available, most clinicians consider liver transplantation an investigational approach for metastatic pancreatic neuroendocrine tumors, including somatostatinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691420#H691420\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Liver transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23750348\">",
"    <span class=\"h3\">",
"     Chemotherapy and novel treatment approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic chemotherapy is only weakly active against metastatic pancreatic neuroendocrine tumors. Anecdotal reports have described both a reduction in tumor mass and a remission of systemic symptoms with chemotherapy in patients with somatostatinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/3,22\">",
"     3,22",
"    </a>",
"    ]. The traditional regimen of choice has been",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/30/9702?source=see_link\">",
"     streptozocin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    . Although objective response rates as high as 69 percent were initially reported for metastatic pancreatic neuroendocrine tumors, with decreases in endocrine hyperfunction, the true radiologic response rate is probably between 10 and 40 percent. Furthermore, few patients with somatostatinoma have been included in published reports. The uncertain efficacy, as well as the toxicity of this regimen, which can include nausea, prolonged myelosuppression, and renal failure, has prevented its widespread acceptance as a standard first-line therapy for patients with metastatic pancreatic endocrine tumors.",
"   </p>",
"   <p>",
"    More recently, antitumor activity has also been shown for regimens containing the orally active alkylating agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    . In the absence of comparative trials, the choice of first-line",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/30/9702?source=see_link\">",
"      streptozocin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"      doxorubicin",
"     </a>",
"    </span>",
"    or a temozolomide-based regimen must be individualized, taking into account the convenience of oral rather than intravenous treatment, performance status, and the anticipated side effect profile of both combinations. This topic is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948956#H190948956\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Cytotoxic chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The modest efficacy of conventional cytotoxic chemotherapy has prompted the development of novel therapeutic approaches for patients with advanced pancreatic neuroendocrine tumors. In the United States, two molecularly targeted agents were approved for treatment of advanced pancreatic neuroendocrine tumors in 2011:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    , a small molecule multitargeted tyrosine kinase inhibitor, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    , an inhibitor of the mammalian target of rapamycin (mTOR). These agents, and other forms of novel therapy, including peptide receptor radioligand therapy, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949026#H190949026\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Molecularly targeted therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949119#H190949119\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Peptide receptor radioligand therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis with any therapy is poor when patients present with metastatic disease. In one series of 12 patients, the two- and five-year survival rates were about 30 and 15 percent, respectively, with better outcomes in patients with duodenal somatostatinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/23\">",
"     23",
"    </a>",
"    ]. However, other authors reported a five year survival of 56 percent in 44 patients with metastatic somatostatinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence from which to make recommendations for follow-up after resection of a somatostatinoma. Guidelines from the National Comprehensive Cancer Network based upon expert consensus include the following recommendations for follow-up after treatment of pancreatic neuroendocrine tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3623/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three and six months postresection &ndash; History and physical examination, fasting plasma somatostatin level, and",
"      <span class=\"nowrap\">",
"       CT/MRI.",
"      </span>",
"     </li>",
"     <li>",
"      Long-term &ndash; History and physical examination with tumor markers every six to 12 months for years 1 to 3, and as clinically indicated thereafter. Imaging studies are recommended only as clinically indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Somatostatinomas are rare neuroendocrine tumors of D cell origin that contain and sometimes secrete excessive amounts of somatostatin (",
"      <a class=\"graphic graphic_figure graphicRef80502 \" href=\"UTD.htm?20/60/21447\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The most common symptoms are abdominal pain and weight loss. Tumors localized within the pancreas sometimes cause the three classic findings of the somatostatinoma syndrome, including diabetes mellitus, cholelithiasis, and diarrhea with steatorrhea. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Somatostatinomas are usually detected as pancreatic or duodenal masses in the course of evaluating patients with abdominal pain, jaundice,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      weight loss. If a somatostatinoma is suspected preoperatively on the basis of the classical triad of diabetes, gallstones, and steatorrhea, or if a pancreatic neuroendocrine tumor is suspected based on the finding of a mass in the pancreas or duodenum, a fasting plasma somatostatin should be measured. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis, localization, and staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tumor localization is usually accomplished by cross sectional imaging with computed tomography (CT) or magnetic resonance imaging (MRI). If the primary tumor is not visualized on cross sectional imaging, endoscopic ultrasound, or somatostatin receptor scintigraphy may be needed. (See",
"      <a class=\"local\" href=\"#H390421\">",
"       'Localization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As with other neuroendocrine tumors, surgical resection is the treatment of choice. However, because 75 percent of patients have tumors that have metastasized by the time the diagnosis is made, curative surgery is often not possible. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prognosis is generally poor when patients present with metastatic disease, although five-year survival as high as 56 percent has been reported. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment options for metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/1\">",
"      Friesen SR. Update on the diagnosis and treatment of rare neuroendocrine tumors. Surg Clin North Am 1987; 67:379.",
"     </a>",
"    </li>",
"    <li>",
"     Jensen RT, Norton JA. Endocrine neoplasms of the pancreas. In: Textbook of Gastroenterology, Yamada T (Ed), JB Lippincott Co, Philadelphia 1995. p.2131.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/3\">",
"      Harris GJ, Tio F, Cruz AB Jr. Somatostatinoma: a case report and review of the literature. J Surg Oncol 1987; 36:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/4\">",
"      Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 1999; 18:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/5\">",
"      Ohwada S, Joshita T, Ishihara T, et al. Primary liver somatostatinoma. J Gastroenterol Hepatol 2003; 18:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/6\">",
"      Angeletti S, Corleto VD, Schillaci O, et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 1998; 42:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/7\">",
"      Mao C, Shah A, Hanson DJ, Howard JM. Von Recklinghausen's disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. J Surg Oncol 1995; 59:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/8\">",
"      Garbrecht N, Anlauf M, Schmitt A, et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 2008; 15:229.",
"     </a>",
"    </li>",
"    <li>",
"     Snow ND, Liddle RA. Neuroendocrine Tumors. In: Gastrointestinal Cancers: Biology, Diagnosis and Therapy, Rustgi AK (Ed), Lippincott-Raven, Philadelphia 1995. p.585.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/10\">",
"      O'Brien TD, Chejfec G, Prinz RA. Clinical features of duodenal somatostatinomas. Surgery 1993; 114:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/11\">",
"      Suzuki H, Kuwano H, Masuda N, et al. Diagnostic usefulness of FDG-PET for malignant somatostatinoma of the pancreas. Hepatogastroenterology 2008; 55:1242.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York  Vol 2010, p.241.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/13\">",
"      Bilimoria KY, Bentrem DJ, Merkow RP, et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007; 205:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/14\">",
"      Contessa JN, Griffith KA, Wolff E, et al. Radiotherapy for pancreatic neuroendocrine tumors. Int J Radiat Oncol Biol Phys 2009; 75:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/15\">",
"      Strosberg J, Hoffe S, Gardner N, et al. Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology 2007; 85:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/16\">",
"      Tennvall J, Ljungberg O, Ahr&eacute;n B, et al. Radiotherapy for unresectable endocrine pancreatic carcinomas. Eur J Surg Oncol 1992; 18:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/17\">",
"      Torrisi JR, Treat J, Zeman R, Dritschilo A. Radiotherapy in the management of pancreatic islet cell tumors. Cancer 1987; 60:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/18\">",
"      Anene C, Thompson JS, Saigh J, et al. Somatostatinoma: atypical presentation of a rare pancreatic tumor. Am J Gastroenterol 1995; 90:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/19\">",
"      Eriksson B, Oberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993; 32:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/20\">",
"      O'Dorisio TM, Mekhjian HS, Gaginella TS. Medical therapy of VIPomas. Endocrinol Metab Clin North Am 1989; 18:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/21\">",
"      Moug SJ, Leen E, Horgan PG, Imrie CW. Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma. Pancreatology 2006; 6:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/22\">",
"      Konomi K, Chijiiwa K, Katsuta T, Yamaguchi K. Pancreatic somatostatinoma: a case report and review of the literature. J Surg Oncol 1990; 43:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3623/abstract/23\">",
"      Hamy A, Heymann MF, Bodic J, et al. [Duodenal somatostatinoma. Anatomic/clinical study of 12 operated cases]. Ann Chir 2001; 126:221.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2608 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_34_3623=[""].join("\n");
var outline_f3_34_3623=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS, LOCALIZATION, AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H390421\">",
"      Localization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Staging system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Radiation therapy for nonsurgical candidates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment options for metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23750494\">",
"      - Octreotide and interferon alfa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23750312\">",
"      - Liver-directed therapy for metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23750320\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23750327\">",
"      Hepatic artery embolization and chemoembolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23750334\">",
"      RFA and cryoablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23750341\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23750348\">",
"      - Chemotherapy and novel treatment approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2608\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2608|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/60/21447\" title=\"figure 1\">",
"      Islets of Langerhans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2608|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/32/43532\" title=\"table 1\">",
"      TNM panc endo exo CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/42/4780\" title=\"table 2\">",
"      Survival rates following resection of a pancreatic neuroendocrine tumor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/29/4567?source=related_link\">",
"      Physiology of somatostatin and its analogues",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_34_3624="Headache syndromes other than migraine";
var content_f3_34_3624=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Headache syndromes other than migraine",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/34/3624/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/34/3624/contributors\">",
"     Zahid H Bajwa, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/34/3624/contributors\">",
"     Ashraf Sabahat, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/34/3624/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/34/3624/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/34/3624/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/34/3624/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/34/3624/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache is a common complaint among patients presenting to primary care physicians. Most headaches are benign and not associated with a potentially life-threatening illness (eg, meningitis, brain tumor, or subarachnoid hemorrhage). The history and physical examination are the keys to distinguishing potentially serious from benign headaches (",
"    <a class=\"graphic graphic_table graphicRef68064 \" href=\"UTD.htm?40/58/41899\">",
"     table 1",
"    </a>",
"    ). Diagnostic studies such as CT scanning, MRI, and lumbar puncture are rarely necessary.",
"   </p>",
"   <p>",
"    Headache syndromes other than migraine will be briefly reviewed here, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tension type headache",
"     </li>",
"     <li>",
"      The trigeminal autonomic cephalalgias, including cluster headache",
"     </li>",
"     <li>",
"      Chronic daily headache, including medication overuse headache",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Migraine headaches and the evaluation for headaches with a potentially serious underlying pathology are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34615?source=see_link\">",
"     \"Evaluation of headache in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32953?source=see_link\">",
"     \"Headache, migraine, and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TENSION TYPE HEADACHE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tension-type headache (TTH) is the most prevalent headache in the general population. The typical presentation of a TTH attack is that of a mild to moderate intensity, bilateral, nonthrobbing headache without other associated features (",
"    <a class=\"graphic graphic_table graphicRef79672 \" href=\"UTD.htm?42/32/43531\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The revised IHS classification distinguishes three subtypes of tension type headache:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infrequent episodic TTH with headache episodes less than one day a month",
"     </li>",
"     <li>",
"      Frequent episodic TTH with headache episodes 1 to 14 days a month",
"     </li>",
"     <li>",
"      Chronic TTH with headaches 15 or more days a month",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of TTH are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32441?source=see_link\">",
"     \"Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute treatment options for TTH include simple analgesics such as oral NSAIDs for patients with episodic TTH. Combination analgesics containing caffeine are also useful. Preventive treatment is appropriate for most patients with chronic TTH and for many patients with frequent episodic TTH. Tricyclic antidepressants, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    , and behavioral therapy (eg, stress management) are the mainstays of preventive treatment for TTH.",
"   </p>",
"   <p>",
"    The treatment of TTH is reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37079?source=see_link\">",
"     \"Tension-type headache in adults: Acute treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1433?source=see_link\">",
"     \"Tension-type headache in adults: Preventive treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TRIGEMINAL AUTONOMIC CEPHALALGIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trigeminal autonomic cephalalgias are a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with ipsilateral cranial autonomic features [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3624/abstract/1\">",
"     1",
"    </a>",
"    ]. The trigeminal autonomic cephalalgias include cluster headache, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27174?source=see_link\">",
"     \"Pathophysiology of the trigeminal autonomic cephalalgias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite their common elements, the trigeminal autonomic cephalalgias differ in attack duration and frequency, as well as the response to therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cluster headache has the longest attack duration (minutes to hours) and relatively low attack frequency (up to eight a day)",
"     </li>",
"     <li>",
"      Paroxysmal hemicrania has intermediate duration (minutes) and intermediate attack frequency (up to 40 a day)",
"     </li>",
"     <li>",
"      SUNCT has the shortest attack duration (seconds to minutes) and the highest attack frequency (up to 200 a day)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cluster headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cluster headache is characterized by attacks of severe unilateral orbital, supraorbital, or temporal pain, accompanied by autonomic phenomena. Unilateral autonomic symptoms are ipsilateral to the pain and may include ptosis, miosis, lacrimation, conjunctival injection, rhinorrhea, and nasal congestion. Attacks usually last 15 to 180 minutes.",
"   </p>",
"   <p>",
"    In its typical form, cluster headache is unmistakable. The diagnosis is exclusively a clinical one (",
"    <a class=\"graphic graphic_table graphicRef80843 \" href=\"UTD.htm?12/58/13228\">",
"     table 3",
"    </a>",
"    ). Cluster headache is relatively uncommon; the prevalence is less than 1 percent. Men are affected more commonly than women. In the episodic type of cluster headache, attacks occur daily, usually one to eight times a day for some weeks, followed by a period of remission. The chronic type of cluster headache lacks sustained remissions.",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of cluster headache are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oxygen inhalation and subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    are first-line treatments for acute cluster headache attacks. Other agents with some evidence of effectiveness include ergots,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Preventive therapy should be started as soon as possible at the onset of a cluster episode. The goal is to suppress attacks over the expected duration of the cluster period. An effective preventive regimen is of utmost importance because patients typically have one to eight cluster headaches a day, and repeated use of abortive medications may result in toxicity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rebound.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    is the agent of choice for the preventive therapy of cluster headache. Other agents that may be effective include glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    and methysergide.",
"   </p>",
"   <p>",
"    The treatment of cluster headache is reviewed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3898?source=see_link\">",
"     \"Cluster headache: Acute and preventive treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Paroxysmal hemicrania",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal hemicrania is a rare condition with a female predominance. It may begin at any age, although onset usually occurs during adulthood. Patients typically have unilateral, brief, severe attacks of pain associated with cranial autonomic features that recur several times per day. The headache is strictly unilateral, most often in the ophthalmic trigeminal distribution. The headache usually lasts 2 to 30 minutes, but may go on for up to two hours. Ipsilateral cranial autonomic features, such as lacrimation, conjunctival injection, nasal congestion, or rhinorrhea, frequently accompany the headache. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=see_link\">",
"     \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9112?source=see_link\">",
"     \"Paroxysmal hemicrania: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paroxysmal hemicrania, unlike cluster headache and SUNCT, responds in a dramatic and absolute fashion to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     SUNCT and SUNA syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) are rare syndromes that are classified with cluster headache as trigeminal autonomic cephalalgias [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3624/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SUNCT and SUNA are characterized by sudden brief attacks of severe unilateral head pain in orbital, periorbital, or temporal regions, accompanied by ipsilateral cranial autonomic symptoms. In SUNCT, the ipsilateral autonomic symptoms consist of both conjunctival injection and lacrimation. In SUNA, the autonomic symptoms may include only one of conjunctival injection or lacrimation, or there may be other cranial autonomic symptoms (eg, nasal congestion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rhinorrhea, or eyelid edema). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=see_link\">",
"     \"SUNCT and SUNA headache syndromes: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SUNCT and SUNA were once considered to be refractory to therapy, but appear to be responsive to acute treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    . Limited data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    may be moderately effective as preventive therapy for SUNCT and SUNA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2264?source=see_link\">",
"     \"SUNCT and SUNA headache syndromes: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CHRONIC DAILY HEADACHE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic daily headache (CDH) is not a specific headache type, but a syndrome that encompasses other primary headaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37830?source=see_link\">",
"     \"Overview of chronic daily headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"chronic\" refers either to the frequency of headaches or to the duration of the disease, depending upon the specific headache type. With headache subtypes of long duration (ie, four hours or more), \"chronic\" indicates a headache frequency of 15 or more days a month for longer than three months in the absence of organic pathology. These headache subtypes are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic migraine headache (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7128?source=see_link\">",
"       \"Chronic migraine\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chronic tension-type headache (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32441?source=see_link\">",
"       \"Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Medication overuse headache (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35879?source=see_link\">",
"       \"Medication overuse headache: Etiology, clinical features, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hemicrania continua (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43942?source=see_link\">",
"       \"Hemicrania continua\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      New daily persistent headache (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2968?source=see_link\">",
"       \"New daily persistent headache\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transformed migraine and medication overuse headache are two of the most common types that lead to CDH.",
"   </p>",
"   <p>",
"    With headache subtypes of shorter duration (ie, less than four hours), \"chronic\" refers to a prolonged duration of the condition itself without remission. The headache subtypes in this category are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic cluster headache (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"       \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chronic paroxysmal hemicrania (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=see_link\">",
"       \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypnic headache (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5700?source=see_link\">",
"       \"Hypnic headache\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      SUNCT (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=see_link\">",
"       \"SUNCT and SUNA headache syndromes: Clinical features and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Primary stabbing headache (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=see_link\">",
"       \"Primary stabbing headache\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients with CDH have either chronic tension-type headache or chronic migraine.",
"   </p>",
"   <p>",
"    The diagnosis of CDH is suspected on the basis of a compatible headache history. Other disorders causing secondary headache must be excluded. The management of CDH depends on the type of background headache and the presence or absence of medication overuse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Medication overuse headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medication overuse headache (MOH) is not a primary headache but frequently coexists with primary chronic daily headache. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35879?source=see_link\">",
"     \"Medication overuse headache: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All acute symptomatic medications used to treat headaches have the potential for causing MOH. The risk for MOH appears to vary as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Highest with opioids, butalbital-containing combination analgesics, and",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"        aspirin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"        acetaminophen",
"       </a>",
"       /caffeine",
"      </span>",
"      combinations",
"     </li>",
"     <li>",
"      Intermediate to high with triptans",
"     </li>",
"     <li>",
"      Lowest with nonsteroidal antiinflammatory drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The development of MOH is usually preceded by an episodic headache disorder, typically migraine or tension-type headache, that has been treated with frequent and excessive amounts of acute symptomatic medications.",
"   </p>",
"   <p>",
"    Withdrawal of the overused medication as soon as possible is the treatment of choice for MOH. It is also important to educate patients about the detrimental effects of analgesic overuse. Bridge (transitional) therapy may be useful during drug withdrawal to provide symptomatic relief. For most patients, a preventive (prophylactic) medication aimed at the suspected background primary headache disorder (eg, migraine) should be initiated either during or immediately following withdrawal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17161?source=see_link\">",
"     \"Medication overuse headache: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To prevent MOH relapse, triptan or over-the-counter combination analgesic use should be limited to nine or fewer days a month on average, and NSAIDs to 15 or fewer days a month. Butalbital-containing analgesics and opioids should be avoided because of their high risk for MOH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OTHER CAUSES OF HEADACHE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other disorders may present with headaches, including brain tumor, cerebral venous thrombosis, giant cell arteritis, low cerebrospinal fluid pressure, trauma, and ruptured intracranial aneurysms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Brain tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headaches occur in approximately 50 percent of patients with brain tumors. One study examined 111 consecutive patients with primary or metastatic brain tumors identified by CT or MRI to characterize brain tumor headache [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3624/abstract/2\">",
"     2",
"    </a>",
"    ]. Headaches were present in 48 percent and equally affected those with primary and metastatic tumors. The headaches were similar to tension type in 77 percent, migraine in 9 percent, and other types in 14 percent. The typical headache was bifrontal but worse ipsilaterally; it was the worst symptom in about one-half of patients. In contrast to tension type headaches, brain tumor headaches were worse with bending over in 32 percent, and nausea or vomiting was present in 40 percent. Worsening headache may also follow maneuvers that raise intrathoracic pressure, such as coughing, sneezing, or the Valsalva maneuver. The \"classic\" early morning brain tumor headache was uncommon.",
"   </p>",
"   <p>",
"    Findings suggesting that headaches are caused by a brain tumor include nausea, vomiting, worsening of headache with changes in body position, an abnormal neurologic examination, and a significant change in prior headache pattern. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"     \"Clinical presentation and diagnosis of brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cerebral venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral venous thrombosis (CVT) is an uncommon but serious disorder. Many cases have been linked to inherited and acquired thrombophilias, pregnancy, puerperium, infection, and malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link&amp;anchor=H4#H4\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Headache is the most common clinical manifestation, occurring in up to 90 percent. The headache frequently precedes other symptoms, is typically diffuse, and often severe. Headache onset may be \"thunderclap,\" acute, or progressive. Rarely, headache may be the only symptom of CVT. Other clinical manifestations can include papilledema, visual loss, focal or generalized seizures, focal neurologic deficits, confusion, altered consciousness, and coma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link&amp;anchor=H5#H5\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\", section on 'Clinical aspects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is confirmed by CT venography, MRI combined with MR venography, conventional angiography, surgery, or autopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link&amp;anchor=H16#H16\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment, which is started as soon as the diagnosis is confirmed, consists of reversing the underlying cause when known, control of seizures and intracranial hypertension, and anticoagulation. Local thrombolysis may be indicated in rare cases unresponsive to adequate anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=see_link\">",
"     \"Treatment and prognosis of cerebral venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Giant cell arteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant cell (temporal) arteritis is a chronic vasculitis of large and medium sized vessels. A new type of headache occurs in two-thirds of affected individuals. The head pain tends to be located over the temporal areas but can be frontal or occipital in location. The headaches may be mild or severe. The course is also variable; the headaches may become progressively worse, but can subside before treatment is started in some cases. Tender temporal or occipital arteries are found in approximately one-third of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Indomethacin responsive headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    responsive headache is not used in the International Headache Society (IHS) classification. However, in our view it is an interesting and useful group of disorders. Several syndromes have emerged with selective responsiveness to indomethacin:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary cough headache (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22101?source=see_link\">",
"       \"Primary cough headache\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Idiopathic stabbing headache (ice-pick headache) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=see_link\">",
"       \"Primary stabbing headache\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Episodic and chronic paroxysmal hemicrania (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=see_link\">",
"       \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     Indomethacin",
"    </a>",
"    , 75 to 200 mg daily in divided doses, stops the headaches associated with these syndromes. The benefit is typically apparent within a couple of days of an adequate dose.",
"   </p>",
"   <p>",
"    Primary exertional headache, primary headache associated with sexual activity, and hemicrania continua may also respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , but these disorders can improve with other analgesic and prophylactic drugs as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44356?source=see_link\">",
"     \"Primary exertional headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16054?source=see_link\">",
"     \"Primary headache associated with sexual activity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43942?source=see_link\">",
"     \"Hemicrania continua\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Low cerebrospinal fluid pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who present with headache that is relieved with recumbency and exacerbated with upright posture, the diagnosis of spontaneous low cerebrospinal fluid (CSF) pressure headache should be considered. An additional major feature of this headache syndrome is diffuse meningeal enhancement on brain MRI. The accepted etiology is CSF leakage, which may occur in the context of rupture of an arachnoid membrane. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another headache with a similar pathophysiology is post-lumbar puncture headache (PLPHA), which occurs in 10 to 30 percent of patients following lumbar puncture. Patients characteristically present with frontal or occipital headache within 12 to 24 hours of the procedure. The headache is exacerbated in an upright position and improved in the supine position. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20198?source=see_link\">",
"     \"Post-lumbar puncture headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Post traumatic headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IHS defines post traumatic headaches as occurring within seven days after head trauma. There are many variants of post traumatic headache. Tension headache is the most frequent headache type occurring as part of the postconcussion syndrome. Other post traumatic headache types include migraine, occipital neuralgia, temporomandibular joint dysfunction, and others. In general, the symptoms and treatment approach to post traumatic headache do not differ from that outside the trauma setting. Post traumatic headaches are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33929?source=see_link\">",
"     \"Postconcussion syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ruptured intracranial aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;A ruptured intracranial aneurysm causes a severe headache of sudden onset that patients often characterize as \"the worst headache of their life.\" A decreased level of consciousness and stiff neck are common accompanying features. Some patients (30 to 60 percent) experience a minor leak prior to rupture. This leak may be manifested clinically as a \"sentinel headache,\" which typically presents as a severe headache lasting for only a few minutes without associated neurologic abnormalities.",
"   </p>",
"   <p>",
"    The work-up of patients with a suspected subarachnoid hemorrhage begins with a noncontrast head CT scan. If head CT is negative, a lumbar puncture must be performed, since a minor leak may be missed on CT. The sensitivity of head CT for detecting SAH is highest in the first 12 hours after SAH (nearly 100 percent) and then progressively declines over time to about 58 percent at day five. This issue is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link&amp;anchor=H26#H26\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Sinus headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although sinus headache is commonly diagnosed by physicians and self-diagnosed by patients, acute or chronic sinusitis appears to be an uncommon cause of recurrent headaches, and many patients presenting with sinus headache turn out to have migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3624/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Confusion with migraine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The definition of sinus headache suffers from a lack of consensus among expert groups, with different working diagnostic criteria offered by the International Headache Society (IHS) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3624/abstract/1\">",
"     1",
"    </a>",
"    ] and various otolaryngology groups.",
"   </p>",
"   <p>",
"    True acute sinus headache is recognized by the IHS criteria, but it occurs in conjunction with acute sinusitis, fever, and purulent discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3624/abstract/1\">",
"     1",
"    </a>",
"    ]. The absence of these features should prompt consideration of migraine as the underlying etiology of headache associated with sinus pain or pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3624/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features of acute and chronic rhinosinusitis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Confusion with migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomic features characteristically occur in cluster headaches and are also common with migraine headache. These symptoms may include nasal congestion, rhinorrhea, tearing, color and temperature change, and changes in pupil size. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prominence of sinus symptoms often leads to the misdiagnosis of \"sinus headache\" in patients who meet diagnostic criteria for migraine or, less often, tension-type headache. This point is illustrated by an observational study that enrolled 2991 patients with a history of physician or self-diagnosed sinus headache and no previous history of migraine; 88 percent of these patients fulfilled IHS criteria for migraine or migrainous headache, and 8 percent fulfilled IHS criteria for tension-type headache [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3624/abstract/4\">",
"     4",
"    </a>",
"    ]. In the patients with migraine or migrainous headache, sinus pain, pressure, and congestion commonly occurred in association with typical migraine features such as pulsing head pain, and sensitivity to activity, light, and sound (",
"    <a class=\"graphic graphic_figure graphicRef66523 \" href=\"UTD.htm?36/8/37006\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pain related purely to sinus conditions may have some features that aid in distinguishing it from migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3624/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Sinus-related pain or headache is typically described as a pressure-like or dull sensation that is usually bilateral and periorbital. However, it can be unilateral with deviated septum, middle or inferior turbinate hypertrophy, or unilateral sinus disease. In addition, sinus-related pain is typically associated with nasal obstruction or congestion, lasts for days at a time, and is usually not associated with nausea, vomiting, photophobia, or sonophobia.",
"   </p>",
"   <p>",
"    The severity, extent and location of sinus-related pain does not correlate with the extent or location of mucosal disease as revealed by imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3624/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Consensus guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;An interdisciplinary ad-hoc committee published guidelines in 2005 to address the evidence from multiple disciplines that sinus headache (headache of rhinogenic origin) and migraine may be confused with one another [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3624/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. The following guidelines emerged:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A stable pattern of recurrent headaches that interfere with daily function is most likely migraine.",
"     </li>",
"     <li>",
"      Recurrent self-limited headaches associated with rhinogenic symptoms are most likely migraine.",
"     </li>",
"     <li>",
"      Prominent rhinogenic symptoms with headache as one of several symptoms should be evaluated carefully for otolaryngologic conditions. The preferred standard is nasal endoscopy. However, MRI and CT can be substituted.",
"     </li>",
"     <li>",
"      Headache associated with fever and purulent nasal discharge is likely rhinogenic in origin.",
"     </li>",
"     <li>",
"      Referral to a headache specialist should be considered for new-onset headache, frequent (more than once a week) headache, headache associated with neurologic symptoms or signs, or headache that does not respond adequately to conventional therapy.",
"     </li>",
"     <li>",
"      Patients with migraine with no evidence of infection should be given a trial of migraine-specific medication and seen for a follow-up evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=see_link\">",
"       \"Acute treatment of migraine in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with noninfectious rhinogenic symptoms who have headache as a minor symptom should be given nasal glucocorticoids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      selective nasal antihistamines.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=see_link\">",
"       \"Patient information: Headache (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/51/16179?source=see_link\">",
"       \"Patient information: Headache causes and diagnosis in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/59/42931?source=see_link\">",
"       \"Patient information: Headache treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3624/abstract/1\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3624/abstract/2\">",
"      Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology 1993; 43:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3624/abstract/3\">",
"      Cady RK, Schreiber CP. Sinus headache or migraine? Considerations in making a differential diagnosis. Neurology 2002; 58:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3624/abstract/4\">",
"      Schreiber CP, Hutchinson S, Webster CJ, et al. Prevalence of migraine in patients with a history of self-reported or physician-diagnosed \"sinus\" headache. Arch Intern Med 2004; 164:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3624/abstract/5\">",
"      Cady RK, Dodick DW, Levine HL, et al. Sinus headache: a neurology, otolaryngology, allergy, and primary care consensus on diagnosis and treatment. Mayo Clin Proc 2005; 80:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3624/abstract/6\">",
"      Tarabichi M. Characteristics of sinus-related pain. Otolaryngol Head Neck Surg 2000; 122:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3624/abstract/7\">",
"      Levine HL, Setzen M, Cady RK, et al. An otolaryngology, neurology, allergy, and primary care consensus on diagnosis and treatment of sinus headache. Otolaryngol Head Neck Surg 2006; 134:516.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3350 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-BD9846CABD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_34_3624=[""].join("\n");
var outline_f3_34_3624=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TENSION TYPE HEADACHE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TRIGEMINAL AUTONOMIC CEPHALALGIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cluster headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Paroxysmal hemicrania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUNCT and SUNA syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CHRONIC DAILY HEADACHE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Medication overuse headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OTHER CAUSES OF HEADACHE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Brain tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Giant cell arteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Indomethacin responsive headaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Low cerebrospinal fluid pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Post traumatic headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ruptured intracranial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Sinus headache",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Confusion with migraine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Consensus guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3350\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3350|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/8/37006\" title=\"figure 1\">",
"      Sinus symptoms with migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3350|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/58/41899\" title=\"table 1\">",
"      Common headache syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/32/43531\" title=\"table 2\">",
"      Tension-type headache criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/58/13228\" title=\"table 3\">",
"      Diagnostic criteria cluster headache",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=related_link\">",
"      Acute treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7128?source=related_link\">",
"      Chronic migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3898?source=related_link\">",
"      Cluster headache: Acute and preventive treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=related_link\">",
"      Cluster headache: Epidemiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34615?source=related_link\">",
"      Evaluation of headache in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32953?source=related_link\">",
"      Headache, migraine, and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43942?source=related_link\">",
"      Hemicrania continua",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5700?source=related_link\">",
"      Hypnic headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35879?source=related_link\">",
"      Medication overuse headache: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17161?source=related_link\">",
"      Medication overuse headache: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2968?source=related_link\">",
"      New daily persistent headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37830?source=related_link\">",
"      Overview of chronic daily headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=related_link\">",
"      Paroxysmal hemicrania: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9112?source=related_link\">",
"      Paroxysmal hemicrania: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27174?source=related_link\">",
"      Pathophysiology of the trigeminal autonomic cephalalgias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/51/16179?source=related_link\">",
"      Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/59/42931?source=related_link\">",
"      Patient information: Headache treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20198?source=related_link\">",
"      Post-lumbar puncture headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33929?source=related_link\">",
"      Postconcussion syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22101?source=related_link\">",
"      Primary cough headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44356?source=related_link\">",
"      Primary exertional headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16054?source=related_link\">",
"      Primary headache associated with sexual activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=related_link\">",
"      Primary stabbing headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2264?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37079?source=related_link\">",
"      Tension-type headache in adults: Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32441?source=related_link\">",
"      Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1433?source=related_link\">",
"      Tension-type headache in adults: Preventive treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=related_link\">",
"      Treatment and prognosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_34_3625="Prophylactic total gastrectomy for hereditary diffuse gastric cancer";
var content_f3_34_3625=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prophylactic total gastrectomy for hereditary diffuse gastric cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/34/3625/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/34/3625/contributors\">",
"     Debrah Wirtzfeld, MD, MSc, FRCSC, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/34/3625/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/34/3625/contributors\">",
"     David I Soybel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/34/3625/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/34/3625/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/34/3625/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic total gastrectomy (PTG) is the recommended treatment approach in patients at proven risk for hereditary diffuse gastric cancer (HDGC) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. HDGC is an inherited form of diffuse type gastric cancer (also referred to as linitis plastica) that results from abnormalities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mutations in the CDH1 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Suspicion of a causative gene mutation should occur when a case of diffuse gastric cancer is diagnosed in a family member under the age of 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When multiple cancers, bilateral cancers, cancers at an unusually young age or a high rate of cancer occurrence is noted in a family history, these are \"red flags\" for the presence of a gene mutation and genetic counseling and testing should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2296?source=see_link\">",
"     \"Hereditary diffuse gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylactic total gastrectomy (PTG) for HDGC will be reviewed here. The genetics of this disease, pathogenesis, and screening for HDGC are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2296?source=see_link\">",
"     \"Hereditary diffuse gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33194?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathology and molecular pathogenesis of gastric cancer\", section on 'Diffuse type cancers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MULTIDISCIPLINARY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at risk for DGC should be evaluated and managed in collaboration with a multidisciplinary team including surgeons, geneticists, nutritionists, pathologists, psychologists, and primary care providers. The role of the specialists in preparing these patients for surgery is outlined below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genetic counseling and testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;An experienced geneticist should be involved in providing appropriate genetic counseling and testing for HDGC. Germline CDH1 mutations can also cosegregate with invasive lobular breast cancer in the absence of diffuse gastric cancer, suggesting that gastric cancer is not an obligatory hallmark of families with CDH1 mutations, although this is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/9\">",
"     9",
"    </a>",
"    ]. The lifetime cumulative risk for clinically significant gastric cancer in individuals from these families is &gt;80 percent in both men and women by age 80 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients with CDH1 mutations and no family history of DGC may not be candidates for prophylactic total gastrectomy. Specific criteria for genetic testing and decision making for patients with CHD1 mutations are addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2296?source=see_link&amp;anchor=H6#H6\">",
"     \"Hereditary diffuse gastric cancer\", section on 'Genetic counseling and testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link&amp;anchor=H69480723#H69480723\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Inherited CDH1 mutations and hereditary diffuse gastric cancer syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Alternatives to surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that there is no effective screening tool that can reliably identify early disease, strong consideration should be given to PTG for these patients. However, those who receive a recommendation for prophylactic gastrectomy may understandably decide to postpone or refuse the procedure due to young age, fertility concerns, or fear of surgery with accompanying complications. Unfortunately, there are no reliable screening tests that allow early diagnosis of diffuse gastric cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2296?source=see_link\">",
"     \"Hereditary diffuse gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Surgical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical evaluation should be carried out by a surgeon who is familiar with the intricacies of HDGC, who performs total gastrectomy on a regular basis and can provide pre-operative counseling regarding the risk of gastric cancer, and who is experienced in the management of intraoperative and post-operative complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Age and fertility considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient age, at both extremes, should be a consideration in any discussion of PTG. As with other inherited cancer susceptibility syndromes, the age at which a prophylactic procedure is recommended should be predicated on the presence of a known causative mutation and the age of onset of disease in the pedigree [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/11\">",
"     11",
"    </a>",
"    ]. The potential physical and psychological ramifications of a total gastrectomy should be balanced with the penetrance pattern for a particular kindred.",
"   </p>",
"   <p>",
"    While the mean age of onset of diffuse gastric cancer documented in the literature is approximately 38, there are certain kindreds where the mean age of onset is much younger [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/12\">",
"     12",
"    </a>",
"    ]. Some suggest consideration of total gastrectomy in CDH1 mutation carriers at an age 5 years younger than the youngest family member who developed gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/13\">",
"     13",
"    </a>",
"    ]. Early PTG may be justified in such kindreds due to the observation that disease tends to develop at a younger age in successive generations of affected individuals, a phenomenon referred to as genetic anticipation. Performance of a PTG for HDGC has been reported in a 15 year old patient [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/14\">",
"     14",
"    </a>",
"    ]. As more pedigrees are evaluated, even younger individuals and their families may want to discuss prophylactic surgery. We have recommended that gastrectomy be considered in the early 20s in male mutation carriers and that female mutation carriers be advised on the possible dietary ramifications of PTG on future fertility.",
"   </p>",
"   <p>",
"    There are few data on fertility and pregnancy after PTG, but available data are reassuring. At least three pregnancies following PTG have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/15\">",
"     15",
"    </a>",
"    ]. All three delivered appropriately grown infants at term. Over 150 pregnancies after gastrectomy for various other indications have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Maternal anemia was the only significant complication potentially related to gastrectomy in these pregnancies. As with postbariatric surgery patients, appropriate monitoring and supplementation for likely micronutrient deficiencies after gastrectomy is recommended to reduce the risk of adverse pregnancy outcomes associated with these deficiencies (eg, anemia from iron or B12 deficiency, neural tube defects from folate deficiency).",
"   </p>",
"   <p>",
"    Fertility concerns in women undergoing PTG would be similar to those in other populations with low body weight. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14425?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of treatment of female infertility\", section on 'Low body weight'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link&amp;anchor=H31379385#H31379385\">",
"     \"Anorexia nervosa in adults and adolescents: Medical complications and their management\", section on 'Fertility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At the other extreme, while there is no upper age limit, decision to proceed with PTG should be balanced against competing comorbidities. Patients should be advised that the older they are, the less likely they will eventually show the phenotype, especially in families with a young mean age of onset of gastric cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nutritional education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Education about potential long term vitamin and nutrient concerns should be provided by an experienced dietician [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/18\">",
"     18",
"    </a>",
"    ]. In patients who are undergoing PTG, it is important to communicate that recovery from this operation and return to a new 'normal' eating pattern may take up to a year.",
"   </p>",
"   <p>",
"    These patients will have long term dietary changes. The nutritional deficiencies are similar to those seen in other conditions that lead to decreased nutrient intake or absorption",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased losses. The most common problems are deficiencies of micronutrients (nutrients needed for life in small quantities), including several water-soluble vitamins (eg, vitamin B12), fat-soluble vitamins (eg, vitamins A, D, E, and K), and trace minerals, including iron and calcium. A detailed discussion of nutrient deficiencies is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Postgastrectomy syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be educated about postgastrectomy syndromes, including early dumping syndrome, late hypoglycemic (dumping) syndrome, postvagotomy diarrhea, and alkaline reflux. These can be expected to occur to a greater or lesser extent in almost everyone who undergoes total gastrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/19\">",
"     19",
"    </a>",
"    ]. Education regarding appropriate diet and anti-diarrhea medications are usually effective. Surgical intervention is rarely needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33688?source=see_link&amp;anchor=H10#H10\">",
"     \"Role of surgery in the management of peptic ulcer disease\", section on 'Postgastrectomy syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is advisable that patients speak with others who have undergone this operation and who will be able to act as a source of support during recovery from the operation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Psychiatric evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As patients can be expected to lose up to one third of their body weight following PTG, patients with eating disorders such as bulimia and anorexia nervosa are considered especially high-risk in terms of both the physical and psychological outcomes of PTG. The potential risk of gastric cancer must be weighed against the severity of the anorexia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Family counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female members of these kindreds must be appropriately evaluated for their increased risk of lobular breast cancer and be made aware of the need for high-risk breast cancer evaluation given the elevated risk of lobular breast cancer associated with this condition. Women with CDH1 germline mutations have a 60 percent risk of developing lobular breast cancer by age 80 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/10\">",
"     10",
"    </a>",
"    ]. Men can also develop breast cancer. The exact risk for breast cancer in male mutation carriers has not been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=see_link\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS TO SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There currently exist no absolute contraindications to PTG in patients with a family history of diffuse gastric cancer in whom a pathogenic mutation in CDH-1 is known. However, germline CDH1 mutations can also be cosegregated with invasive lobular breast cancer in the absence of diffuse gastric cancer, suggesting that gastric cancer is not an obligatory hallmark of families with CDH1 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/9\">",
"     9",
"    </a>",
"    ]. Prophylactic gastrectomy may not be indicated in families with CDH1 germline mutations where there is phenotypic expression of invasive lobular cancer but not diffuse gastric cancer. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Genetic counseling and testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The decision to proceed with prophylactic surgery in a hereditary cancer syndrome is one that should be preceded by both genetics and surgical consultation in order to estimate the risk of neoplastic disease and the anticipated reduction that can be achieved through surgical intervention. The risks of the surgery should be well described and understood by the patient.",
"   </p>",
"   <p>",
"    As discussed above in the section on multidisciplinary evaluation for surgery, age extremes, fertility considerations, and eating disorders may represent relative contraindications to surgery. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Multidisciplinary evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative preparation for PTG includes imaging, endoscopy, and colonoscopy to ensure there is not an undiagnosed malignancy, as this would markedly change the preoperative counseling and operative approach. A full bowel preparation before surgery is advised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should undergo computed tomography (CT) evaluation of the abdomen preoperatively to ensure an obvious cancer is not missed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/5\">",
"     5",
"    </a>",
"    ]. Positron emission tomography (PET) scanning is performed only if an undiagnosed gastric cancer is suspected by endoscopy or CT scanning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Endoscopy and colonoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative evaluation should include endoscopy with at least 15 random biopsies of the antrum, incisura, fundus, and body if no gross mucosal abnormalities are noted [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/20\">",
"     20",
"    </a>",
"    ]. The delineation of the gastroesophageal junction and any hiatal herniation should also be noted.",
"   </p>",
"   <p>",
"    Pre-operative endoscopic evaluation should be used to assess the level of the gastroesophageal junction. If a shortened esophagus is identified on endoscopy, this will alter the surgical approach and extension of the incision into the thorax will be needed.",
"   </p>",
"   <p>",
"    If magnifying endoscopy methodology such as narrow band imaging or chromoendoscopy is available, this should be utilized as part of a clinical trial and with the patient's knowledge that is it not a highly sensitive screening test [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=see_link\">",
"     \"Narrow band imaging in Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=see_link\">",
"     \"Chromoendoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Colonoscopy should also be performed preoperatively, as an increased risk of colorectal cancer (2 times the normal population) has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The informed consent should include details of the potential intraoperative, post-operative, and long term effects of PTG.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main intraoperative concerns include blood loss requiring transfusion, potential splenectomy, and the risk of having to convert to a thoraco-abdominal approach if the entire stomach cannot be removed through the abdomen as confirmed by intraoperative frozen section analysis of the proximal gastric mucosal margin.",
"     </li>",
"     <li>",
"      Patients should be made aware of the post-operative risks of bleeding requiring transfusion, anastomotic leak, wound infection, and cardiopulmonary concerns. In elective prophylactic procedures of this magnitude, it may be well advised to inform patients of the low, but recognized, risk of death from this procedure.",
"     </li>",
"     <li>",
"      Long term effects of PTG include weight loss, the risk of vitamin deficiencies, the need for supplementation and long term monitoring, and the risk for post-gastrectomy syndromes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Multidisciplinary evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bowel preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials of bowel preparation in the setting of prophylactic gastrectomy. &nbsp;Although the rate of fistula formation and injury to the colon should be low in this setting, a preoperative clear liquid diet and preoperative bowel preparation is usually recommended to decrease the risk of infection. A diet of clear liquids should be started one to three days prior to surgery, along with laxatives and enemas, or a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"     polyethylene glycol",
"    </a>",
"    (PEG) electrolyte lavage solution (GoLYTELY&reg;). Protocols for bowel preparation are presented separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=see_link\">",
"     \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should receive prophylactic antibiotics within one hour before the initial incision [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The recommended antibiotics are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 to 2 g IV) or, in patients allergic to penicillins and cephalosporins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    plus one of the following:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SURGEON'S SAFETY CHECKLIST FOR PROPHYLACTIC GASTRECTOMY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consent includes discussion of potential blood loss, transfusion, potential splenectomy, potential conversion to thoraco-abdominal approach, anastomotic leaks, vitamin deficiencies, and postgastrectomy syndromes.",
"     </li>",
"     <li>",
"      Patient has been typed and crossed in case blood loss necessitates transfusion.",
"     </li>",
"     <li>",
"      Anesthetic concerns specific to the patient have been reviewed.",
"     </li>",
"     <li>",
"      Proper staplers are available.",
"     </li>",
"     <li>",
"      Prophylactic antibiotics have been administered.",
"     </li>",
"     <li>",
"      Imaging studies have been reviewed and are displayed in the operating room.",
"     </li>",
"     <li>",
"      Appropriate deep venous thromboembolism (DVT) prophylaxis has been ordered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As thoracotomy may be necessary, the patient should be prepped and draped appropriately and the operating room staff will need to be prepared with the proper equipment and instrumentation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SURGICAL TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Please note that technical details such as suture choice presented here reflect the author's preferences and are not meant to imply that these are requirements for successful surgical outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Anesthetic considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general anesthetic is given. The use of non-narcotic thoracic epidural anesthesia with early postoperative mobilization may be considered to expedite the return of GI function [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is positioned in the supine position for approach to total gastrectomy by midline celiotomy. Laparoscopic PTG has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;An upper abdominal incision from the xiphoid process of the sternum to the umbilicus is made and extended as required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;An Omni retractor is used to gain adequate exposure to the gastroesophageal junction. The left triangular ligament of the liver is taken down and retracted superiorly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The resection is initiated by taking down the greater omentum and preserving it with the transverse colon and mesocolon inferiorly (",
"    <a class=\"graphic graphic_figure graphicRef53153 \" href=\"UTD.htm?17/33/17938\">",
"     figure 1",
"    </a>",
"    ). The pylorus is identified and marked with a 3-0 Prolene suture (",
"    <a class=\"graphic graphic_figure graphicRef79793 \" href=\"UTD.htm?4/45/4817\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The right gastric and gastroepiploic vessels are double ligated in sequence (",
"    <a class=\"graphic graphic_figure graphicRef58218 \" href=\"UTD.htm?34/35/35378\">",
"     figure 3",
"    </a>",
"    ). The duodenum is then transected just distal to the pylorus using a gastrointestinal anastomosis stapler (GIA) device (",
"    <a class=\"graphic graphic_figure graphicRef81584 \" href=\"UTD.htm?2/8/2181\">",
"     figure 4",
"    </a>",
"    ). Care is taken to preserve the structures of the portal triad. The duodenal stump is oversewn using a 3-0 Prolene.",
"   </p>",
"   <p>",
"    The dissection is carried cephalad along the lesser curve of the stomach by dividing the gastrohepatic ligament towards the diaphragm. The left gastric vessels are identified and divided (",
"    <a class=\"graphic graphic_figure graphicRef81369 \" href=\"UTD.htm?39/43/40625\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The left vagus nerve should be preserved anteriorly along the course of the distal esophagus. It has been shown that the hepatic and celiac branches of the anterior and posterior vagal nerves, respectively can be preserved even in the setting of a total gastrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. This has been shown to result in a decreased incidence of gallstone formation and diarrhea. Bilateral truncal vagotomy can result in up to a 30 percent risk of both gallstone formation and diarrhea. This can be reduced to 5 percent or less if both the celiac and hepatic branches can be preserved.",
"   </p>",
"   <p>",
"    The greater curve is harvested just outside the gastroepiploic arcade. The lesser gastric vessels are taken with preservation of the spleen.",
"   </p>",
"   <p>",
"    The esophagus is encircled with a Penrose drain and the crus of the diaphragm is taken down bilaterally. Following skeletonization of the distal esophagus, four stay sutures of 2-0 Prolene are placed circumferentially in the esophagus approximately 2 cm proximal to the presumed gastroesophageal junction. An automatic pursestringer and circular stapling device and knife are used to transect the distal esophagus (",
"    <a class=\"graphic graphic_figure graphicRef71227 \" href=\"UTD.htm?37/63/38901\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Frozen sections of the proximal and distal gastric margins should be obtained in order to ensure that all stomach tissue has been removed. No gastric mucosa should be identified. If preoperative endoscopic evaluation identified a shortened esophagus, extension into the left thorax may be necessary in order to achieve an adequate proximal margin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Extent of nodal dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodes that are readily harvested with the gastrectomy specimen are removed. No formal lymph node dissection (D0 lymphadenectomy) is performed for PTG.",
"   </p>",
"   <p>",
"    Unlike surgery for invasive malignancy, PTG for HDGC does not include en bloc removal of the lymphovascular drainage basin of the organ resected. The main reason for this is the extremely low chance of identifying an invasive malignancy not previously picked up by screening evaluations. This philosophy is in keeping with that for other common prophylactic surgical procedures including colectomy for hereditary colon cancer syndromes (HNPCC, FAP), bilateral mastectomy for hereditary breast cancer syndromes (BRCA1, BRCA2), and total thyroidectomy (MEN syndromes) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the second meeting of the International Gastric Cancer Linkage Consortium (IGCLC) in November 2009, a pooled analysis of &gt;100 PTG specimens reviewed at a single center showed no evidence of lymph node involvement by traditional nodal assessment. The surgical subcommittee, composed of at least 10 surgeons who perform this procedure within the context of a multidisciplinary team, felt that nodal dissection is not warranted in the prophylactic setting [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is interest in the potential role of sentinel node biopsy with intraoperative evaluation of the node in this setting but no data are currently available to recommend this [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/20\">",
"     20",
"    </a>",
"    ]. Sentinel lymph node biopsy can only be undertaken in the setting of a recognized primary tumor. Although it has been shown that greater than 95 percent of prophylactic gastrectomy specimens harbor microscopic foci of invasive signet ring adenocarcinoma, most of these are not recognized preoperatively. Thus, mapping by means of a directed injection into a localized area of the stomach to guide lymphadenectomy is not possible.",
"   </p>",
"   <p>",
"    A detailed description of the definitions of the extent of lymph node dissections for gastric cancer is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33018?source=see_link&amp;anchor=H12#H12\">",
"     \"Invasive gastric cancer: Surgery and prognosis\", section on 'Extent of lymph node dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best method of reconstruction after gastrectomy will preserve duodenal and jejunal continuity, provide for a functional reservoir and minimize post-gastrectomy functional disturbance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/19,30-33\">",
"     19,30-33",
"    </a>",
"    ]. Duodenal continuity, provided by jejunal interposition between the esophagus and the duodenum is important for preserving absorption of fat soluble vitamins.",
"   </p>",
"   <p>",
"    A prospective randomized trial of 60 patients showed that patients who received duodenal continuity and pouch reconstruction after total gastrectomy had higher body weight and better physiologic regulation of gastrointestinal hormones than those who underwent other reconstructions that did not preserve duodenal passage [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/34\">",
"     34",
"    </a>",
"    ]. Reconstructive techniques that preserve jejunal continuity have been shown to maintain the antegrade movement initiated by the duodenal pacemaker, and as such guard against retrograde and mixed propulsion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The placement of a nasojejunal tube is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 11 randomized trials of gastric pouch reconstruction after total gastrectomy showed that the reconstruction did not increase morbidity or mortality, increase the length of the operation, or the hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients who had a gastric pouch reconstruction had a decrease in dumping syndrome and a significantly improved quality of life as compared with patients who did not undergo pouch reconstruction. In addition, a randomized study of 138 patients who underwent total gastrectomy for gastric cancer, showed that patients who had pouch reconstruction obtained pre-operative quality of life measures by two years, while those without a pouch took five years to obtain pre-operative levels [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/39\">",
"     39",
"    </a>",
"    ]. The optimal size of the pouch has not been well studied. A single institution randomized trial showed that patients with a short (9 cm) pouch (13 patients) had a greater capacity to maintain preoperative oral intake and maintain body weight than patients who had a long (12 cm) pouch (14 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/40\">",
"     40",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    A Hunt-Lawrence type pouch appears to lead to improved outcome over a straight esophago-jejunal anastomosis following total gastrectomy. We prefer the Hunt-Lawrence pouch reconstruction but present both methods of reconstruction here:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Esophagojejunostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anvil of a number 25 end-to-end anastomosis (EEA) stapling device is secured in the distal esophagus and a retrocolic Roux-en-Y esophagojejunostomy is fashioned through the transverse mesocolon using a jejunal limb approximately 40 cm from the Ligament of Treitz (",
"    <a class=\"graphic graphic_figure graphicRef63448 \" href=\"UTD.htm?39/14/40162\">",
"     figure 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Pouch reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;To construct the Hunt-Lawrence pouch, the distal portion of the afferent limb measuring 20 cm in length is brought up posteriorly to the colon, plicated to the proximal efferent limb and held in place by traction sutures. Small stab wounds are made at the midportion of each limb of plicated loops and the GIA stapler is used to perform a side-to side anastomosis at the antimesenteric border of the bowel. The EEA device is then used to perform the anastomosis between the pouch and the esophagus by introducing the long arm of the EEA into the staple line of the limb and out through the center hole of the pouch. The anastomosis is fashioned with the anvil that has been placed in the esophageal opening and enterotomy is then closed transversely using a GIA stapling device. The completed pouch should measure approximately 20 cm in length. The Roux-en-Y is constructed approximately 20 cm below the pouch to reestablish intestinal continuity (",
"    <a class=\"graphic graphic_figure graphicRef76731 \" href=\"UTD.htm?36/52/37697\">",
"     figure 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/41-44\">",
"     41-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Feeding jejunostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A jejunal feeding tube is placed approximately 20 cm distal to the Roux-en-Y entero-enterostomy. We use a 14 French T-tube, with a Stamm type jejunostomy, secured with a double purse-string suture of 3-0 absorbable suture and then anchored to the anterior abdominal wall (",
"    <a class=\"graphic graphic_figure graphicRef76417 \" href=\"UTD.htm?17/4/17473\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are kept nil per os (NPO, meaning nothing by mouth), maintained on intravenous fluids. Jejunal feeding tube is started on postoperative day two, and a Gastrografin swallowing study is done at postoperative day seven, to rule out any anastomotic leaks before starting oral intake. In the absence of a leak, a liquid diet is started and advanced to a soft postgastrectomy diet over 24-48 hours. Frequent small meals, typically three small meals and three snacks a day, protein intake with each meal or snack and reduction of sweets and drinking liquids before or after meals will help avoid dumping syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33688?source=see_link&amp;anchor=H10#H10\">",
"     \"Role of surgery in the management of peptic ulcer disease\", section on 'Postgastrectomy syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Nutritional supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin and mineral supplements will be needed after PTG. Deficiencies in vitamins and minerals can lead to devastating symptoms. These patients are at risk for iron deficiency anemia and megaloblastic anemia as well as mineral and fat soluble vitamin deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Accordingly, supplementation with iron, vitamin B12,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , fat soluble vitamins, and minerals should be provided. This can be done provide in the form of monthly B12 injections or as a sublingual preparation along with a daily multivitamin with iron, folate, and zinc. Calcium and iron levels should be monitored. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major complications after PTG include anastomotic leak, wound infection, sepsis and esophageal stricture [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There were no perioperative deaths in the largest published series of PTG for HDGC [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/50\">",
"     50",
"    </a>",
"    ]. In this series of 17 patients, the average surgical time was 244 minutes and the median length of hospital stay was 13 days. Average blood loss was 1000 ml and three patients required transfusion (17 percent). One patient required conversion to a thoraco-abdominal approach. There were two anastomotic leaks with development of intraabdominal abscesses, requiring operative drainage (11 percent). Three other patients with subclinical leaks found on routine Gastrografin swallow were treated conservatively by maintaining NPO status for 5 to 15 days. Other complications included one right hemicolectomy for a devascularized colon, one infected hematoma, one internal hernia, and three pulmonary emboli.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Long term outcomes following PTG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principle long term morbidities associated with PTG include some degree of malabsorption, dumping syndrome, diarrhea, and a 10 to 15 percent decrease in body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/48,51\">",
"     48,51",
"    </a>",
"    ]. The dumping syndrome and diarrhea are most severe in the initial postoperative period and improve by 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/34/3625/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prophylactic total gastrectomy (PTG) is currently the recommended approach in patients who are mutation positive for hereditary diffuse gastric cancer (HDGC), an inherited form of diffuse type gastric cancer. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multidisciplinary evaluation and preparation of the patient for PTG is crucial for ensuring proper patient selection and need for preoperative counseling. Age and fertility considerations as well as pre-existing eating disorders should be taken into account. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Multidisciplinary evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preoperative preparation includes imaging, endoscopy, and colonoscopy to ensure there is not an undiagnosed malignancy. The level of the gastroesophageal junction should be assessed, as a thoracoabdominal approach may be needed if the esophagus is shortened. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Preoperative preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that no formal lymph node dissection be performed for a prophylactic total gastrectomy. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Surgical techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest pouch reconstruction rather than a straight esophago-jejunal anastomosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Pouch reconstruction appears to improve postoperative quality of life. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Surgical techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major complications after PTG include anastomotic leak, wound infection and sepsis, and esophageal stricture. Long term morbidities associated with PTG include some degree of malabsorption, dumping syndrome, diarrhea, and weight loss. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Morbidity and mortality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/1\">",
"      Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001; 344:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/2\">",
"      Caldas C, Carneiro F, Lynch HT, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet 1999; 36:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/3\">",
"      Rogers WM, Dobo E, Norton JA, et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol 2008; 32:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/4\">",
"      Hebbard PC, Macmillan A, Huntsman D, et al. Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Ann Surg Oncol 2009; 16:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/5\">",
"      Lynch HT, Kaurah P, Wirtzfeld D, et al. Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer 2008; 112:2655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/6\">",
"      Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/7\">",
"      Gayther SA, Gorringe KL, Ramus SJ, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res 1998; 58:4086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/8\">",
"      Grady WM, Willis J, Guilford PJ, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 2000; 26:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/9\">",
"      Xie ZM, Li LS, Laquet C, et al. Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer. Cancer 2011; 117:3112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/10\">",
"      Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010; 47:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/11\">",
"      Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007; 297:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/12\">",
"      Pharoah PD, Guilford P, Caldas C, International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001; 121:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/13\">",
"      Cisco RM, Ford JM, Norton JA. Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgery. Cancer 2008; 113:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/14\">",
"      Blair V, Martin I, Shaw D, et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol 2006; 4:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/15\">",
"      Kaurah P, Fitzgerald R, Dwerryhouse S, Huntsman DG. Pregnancy after prophylactic total gastrectomy. Fam Cancer 2010; 9:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/16\">",
"      PECK DA, WELCH JS, WAUGH JM, WILSON RB. PREGNANCY FOLLOWING GASTRIC RESECTION. Am J Obstet Gynecol 1964; 90:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/17\">",
"      PISANI BJ. Term gestation following total gastrectomy. J Am Geriatr Soc 1958; 6:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/18\">",
"      Adams JF. The clinical and metabolic consequences of total gastrectomy. 3. Notes on metabolic functions, deficiency states, changes in intestinal histology, and radiology. Scand J Gastroenterol 1968; 3:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/19\">",
"      Eagon JC, Miedema BW, Kelly KA. Postgastrectomy syndromes. Surg Clin North Am 1992; 72:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/20\">",
"      Lynch HT, Silva E, Wirtzfeld D, et al. Hereditary diffuse gastric cancer: prophylactic surgical oncology implications. Surg Clin North Am 2008; 88:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/21\">",
"      Kadowaki S, Tanaka K, Toyoda H, et al. Ease of early gastric cancer demarcation recognition: a comparison of four magnifying endoscopy methods. J Gastroenterol Hepatol 2009; 24:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/22\">",
"      Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004; 41:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/23\">",
"      Fry DE. Surgical site infections and the surgical care improvement project (SCIP): evolution of national quality measures. Surg Infect (Larchmt) 2008; 9:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/24\">",
"      Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup, et al. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/25\">",
"      Kehlet H. Fast-track colorectal surgery. Lancet 2008; 371:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/26\">",
"      Francis WP, Rodrigues DM, Perez NE, et al. Prophylactic laparoscopic-assisted total gastrectomy for hereditary diffuse gastric cancer. JSLS 2007; 11:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/27\">",
"      Nunobe S, Hiki N, Fukunaga T, et al. Laparoscopy-assisted pylorus-preserving gastrectomy: preservation of vagus nerve and infrapyloric blood flow induces less stasis. World J Surg 2007; 31:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/28\">",
"      Ando S, Tsuji H. Surgical technique of vagus nerve-preserving gastrectomy with D2 lymphadenectomy for gastric cancer. ANZ J Surg 2008; 78:172.",
"     </a>",
"    </li>",
"    <li>",
"     Yelland, JM. Genetic counseling for inherited cancer syndromes. In: Inherited Cancer Syndromes: Current Clinical Management, Ellis, CN (Ed), Springer-Verlag Inc, New York 2004. p.30.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/30\">",
"      Lawrence W Jr. Reconstruction after total gastrectomy: what is preferred technique? J Surg Oncol 1996; 63:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/31\">",
"      Lehnert T, Buhl K. Techniques of reconstruction after total gastrectomy for cancer. Br J Surg 2004; 91:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/32\">",
"      Sharma D. Choice of digestive tract reconstructive procedure following total gastrectomy: A critical reappraisal. Indian J Surg 2004; 66:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/33\">",
"      El Halabi HM, Lawrence W Jr. Clinical results of various reconstructions employed after total gastrectomy. J Surg Oncol 2008; 97:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/34\">",
"      Schwarz A, B&uuml;chler M, Usinger K, et al. Importance of the duodenal passage and pouch volume after total gastrectomy and reconstruction with the Ulm pouch: prospective randomized clinical study. World J Surg 1996; 20:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/35\">",
"      Hocking MP, Vogel SB, Falasca CA, Woodward ER. Delayed gastric emptying of liquids and solids following Roux-en-Y biliary diversion. Ann Surg 1981; 194:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/36\">",
"      Harrison WD, Hocking MP, Vogel SB. Gastric emptying and myoelectric activity following Roux-en-Y gastrojejunostomy. J Surg Res 1990; 49:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/37\">",
"      Doglietto GB, Papa V, Tortorelli AP, et al. Nasojejunal tube placement after total gastrectomy: a multicenter prospective randomized trial. Arch Surg 2004; 139:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/38\">",
"      Gertler R, Rosenberg R, Feith M, et al. Pouch vs. no pouch following total gastrectomy: meta-analysis and systematic review. Am J Gastroenterol 2009; 104:2838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/39\">",
"      Fein M, Fuchs KH, Thalheimer A, et al. Long-term benefits of Roux-en-Y pouch reconstruction after total gastrectomy: a randomized trial. Ann Surg 2008; 247:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/40\">",
"      Tsujimoto H, Sakamoto N, Ichikura T, et al. Optimal size of jejunal pouch as a reservoir after total gastrectomy: a single-center prospective randomized study. J Gastrointest Surg 2011; 15:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/41\">",
"      Nakane Y, Okumura S, Akehira K, et al. Jejunal pouch reconstruction after total gastrectomy for cancer. A randomized controlled trial. Ann Surg 1995; 222:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/42\">",
"      Menon P, Sunil I, Chowdhury SK, Rao KL. Hunt-Lawrence pouch after total gastrectomy: 4 years follow up. Indian Pediatr 2003; 40:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/43\">",
"      HUNT CJ. Construction of food pouch from segment of jejunum as substitute for stomach in total gastrectomy. AMA Arch Surg 1952; 64:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/44\">",
"      LAWRENCE W Jr. Reservoir construction after total gastrectomy: an instructive case. Ann Surg 1962; 155:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/45\">",
"      Shellito PC, Malt RA. Tube gastrostomy. Techniques and complications. Ann Surg 1985; 201:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/46\">",
"      Harju E. Metabolic problems after gastric surgery. Int Surg 1990; 75:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/47\">",
"      Wastell C. Malabsorptive states after gastrointestinal surgery. Br Med J 1968; 3:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/48\">",
"      Newman EA, Mulholland MW. Prophylactic gastrectomy for hereditary diffuse gastric cancer syndrome. J Am Coll Surg 2006; 202:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/49\">",
"      Lewis FR, Mellinger JD, Hayashi A, et al. Prophylactic total gastrectomy for familial gastric cancer. Surgery 2001; 130:612.",
"     </a>",
"    </li>",
"    <li>",
"     Huntsman, D, University of British Columbia, 2008, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/51\">",
"      Liedman B, Andersson H, Bosaeus I, et al. Changes in body composition after gastrectomy: results of a controlled, prospective clinical trial. World J Surg 1997; 21:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/34/3625/abstract/52\">",
"      Svedlund J, Sullivan M, Liedman B, et al. Quality of life after gastrectomy for gastric carcinoma: controlled study of reconstructive procedures. World J Surg 1997; 21:422.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8041 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-BD889E7001-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_34_3625=[""].join("\n");
var outline_f3_34_3625=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MULTIDISCIPLINARY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Alternatives to surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Surgical evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Age and fertility considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nutritional education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Postgastrectomy syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Psychiatric evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Family counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CONTRAINDICATIONS TO SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Endoscopy and colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bowel preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SURGEON'S SAFETY CHECKLIST FOR PROPHYLACTIC GASTRECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SURGICAL TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Anesthetic considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Extent of nodal dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Reconstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Esophagojejunostomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Pouch reconstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Feeding jejunostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Nutritional supplementation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Long term outcomes following PTG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8041\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8041|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/33/17938\" title=\"figure 1\">",
"      Dissection of greater omentum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/45/4817\" title=\"figure 2\">",
"      Parts of the stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/35/35378\" title=\"figure 3\">",
"      Division of the right gastric and gastroepiploic vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/8/2181\" title=\"figure 4\">",
"      Duodenal transection during total gastrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/43/40625\" title=\"figure 5\">",
"      Division of the left gastric vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/63/38901\" title=\"figure 6\">",
"      Mobilization and transection of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/14/40162\" title=\"figure 7\">",
"      Creation of esophagojejunostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/52/37697\" title=\"figure 8\">",
"      Hunt-Lawrence pouch for esophagojejunostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/4/17473\" title=\"figure 9\">",
"      Feeding jejunostomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=related_link\">",
"      Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=related_link\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2296?source=related_link\">",
"      Hereditary diffuse gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33018?source=related_link\">",
"      Invasive gastric cancer: Surgery and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=related_link\">",
"      Narrow band imaging in Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14425?source=related_link\">",
"      Overview of treatment of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33194?source=related_link\">",
"      Pathology and molecular pathogenesis of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33688?source=related_link\">",
"      Role of surgery in the management of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_34_3626="Lamotrigine: Pediatric drug information";
var content_f3_34_3626=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lamotrigine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"    see \"Lamotrigine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/40/41605?source=see_link\">",
"    see \"Lamotrigine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      LaMICtal&reg;;",
"     </li>",
"     <li>",
"      LaMICtal&reg; ODT&trade;;",
"     </li>",
"     <li>",
"      LaMICtal&reg; XR&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Lamotrigine&reg;;",
"     </li>",
"     <li>",
"      Auro-Lamotrigine;",
"     </li>",
"     <li>",
"      Lamictal&reg;;",
"     </li>",
"     <li>",
"      Mylan-Lamotrigine;",
"     </li>",
"     <li>",
"      PMS-Lamotrigine;",
"     </li>",
"     <li>",
"      ratio-Lamotrigine;",
"     </li>",
"     <li>",
"      Teva-Lamotrigine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage depends on patient's concomitant medications [ie, valproic acid; enzyme-inducing AEDs (specifically phenytoin, phenobarbital, carbamazepine, and primidone); or AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid]. Patients receiving concomitant rifampin or other drugs that induce lamotrigine glucuronidation and increase clearance should follow the same dosing regimen as that used with anticonvulsants that have this effect (eg, phenytoin, phenobarbital, carbamazepine, and primidone). Limited data available; further studies needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Anticonvulsant: Adjunctive (add-on) therapy for refractory seizures:",
"     </b>",
"     PNA 14-28 days: Initial: 2 mg/kg/dose once daily; may increase by 2 mg/kg/day at intervals of at least 7 days to a maximum dose of 10 mg/kg/day; this dosing was described in a prospective, open-label trial that included five neonates (GA not reported) in the study population; all patients had previously received enzyme-inducing agents, such as phenytoin, phenobarbital, and/or carbamazepine; patients were treated with lamotrigine for 3 months (Mikati, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"      see \"Lamotrigine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage depends on patient's concomitant medications [ie, valproic acid; enzyme-inducing AEDs (specifically phenytoin, phenobarbital, carbamazepine, and primidone); or other AEDs not previously mentioned. Patients receiving concomitant rifampin or other drugs that induce lamotrigine glucuronidation and increase clearance should follow the same dosing regimen as that used with anticonvulsants that have similar effects (eg, phenytoin, phenobarbital, carbamazepine, and primidone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anticonvulsant: Adjunctive (add-on) therapy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release formulation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants and Children &lt;24 months (Pi&ntilde;a-Garza, 2008; Pi&ntilde;a-Garza, 2008a):",
"     <b>",
"      Note:",
"     </b>",
"     As reported in the trials, initial doses were administered every other day if necessary due to limited strengths of commercially available products; use of an extemporaneously compounded suspension may allow for more frequent dosing; usually, daily doses are divided into 1-2 doses per day; daily doses in these trials were divided 3 times daily once sufficiently large enough to utilize commercially available products; this was done due to the possible increased clearance of lamotrigine in this age group.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Patients receiving AED regimens",
"      <b>",
"       containing valproic acid or nonenzyme-inducing",
"      </b>",
"      AEDs:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Studies excluded patients &lt;6.7 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 1 and 2: 0.15 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 3 and 4: 0.3 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Maintenance dose: Titrate dose to effect; after week 4, increase dose every week by no more than 0.3 mg/kg/day; maximum maintenance dose: 5.1 mg/kg/day in 3 divided doses not to exceed 200 mg/day; mean final dose required in open-label phase of trial was 3.1 mg/kg/day; n=51 (Pi&ntilde;a-Garza, 2008a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Patients receiving",
"      <b>",
"       enzyme-inducing",
"      </b>",
"      AED regimens (eg, carbamazepine, phenytoin, phenobarbital, or primidone)",
"      <b>",
"       without valproic acid",
"      </b>",
"      :",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 1 and 2: 0.6 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 3 and 4: 1.2 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Maintenance dose: Titrate dose to effect; after week 4, increase dose every week by no more than 1.2 mg/kg/day; maximum maintenance dose: 15.6 mg/kg/day in 3 divided doses not to exceed 400 mg/day; mean final dose required in open-label phase of trial was 8.9 mg/kg/day; n=126 (Pi&ntilde;a-Garza, 2008a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 2-12 years:",
"     <b>",
"      Note:",
"     </b>",
"     <b>",
"      Only whole tablets should be used for dosing",
"     </b>",
"     ; children 2-6 years will likely require maintenance doses at the higher end of recommended range; patients weighing &lt;30 kg may need as much as a 50% increase in maintenance dose, compared with patients weighing &gt;30 kg; titrate dose to clinical effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Patients receiving AEDs",
"      <b>",
"       <span style=\"text-decoration: underline\">",
"        other than",
"       </span>",
"      </b>",
"     </i>",
"     <b>",
"      <i>",
"       carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 1 and 2: 0.3 mg/kg/day in 1-2 divided doses; round dose down to the nearest whole tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 3 and 4: 0.6 mg/kg/day in 2 divided doses; round dose down to the nearest whole tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Maintenance dose: Titrate dose to effect; after week 4, increase dose every 1-2 weeks by a calculated increment; calculate increment as 0.6 mg/kg/day rounded down to the nearest whole tablet; add this amount to the previously administered daily dose; usual maintenance: 4.5-7.5 mg/kg/day in 2 divided doses; maximum: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Patients receiving AED regimens",
"      <b>",
"       containing valproic acid",
"      </b>",
"      :",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 1 and 2: 0.15 mg/kg/day in 1-2 divided doses; round dose down to the nearest whole tablet; use 2 mg every other day for patients weighing &gt;6.7 kg and &lt;14 kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 3 and 4: 0.3 mg/kg/day in 1-2 divided doses; round dose down to the nearest whole tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Maintenance dose: Titrate dose to effect; after week 4, increase dose every 1-2 weeks by a calculated increment; calculate increment as 0.3 mg/kg/day rounded down to the nearest whole tablet; add this amount to the previously administered daily dose; usual maintenance: 1-5 mg/kg/day in 1-2 divided doses; maximum: 200 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Usual maintenance dose in children adding lamotrigine to valproic acid",
"     <b>",
"      alone",
"     </b>",
"     : 1-3 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Patients receiving",
"      <b>",
"       enzyme-inducing",
"      </b>",
"      AED regimens (eg, carbamazepine, phenytoin, phenobarbital, or primidone)",
"      <b>",
"       without valproic acid",
"      </b>",
"      :",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 1 and 2: 0.6 mg/kg/day in 2 divided doses; round dose down to the nearest whole tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 3 and 4: 1.2 mg/kg/day in 2 divided doses; round dose down to the nearest whole tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Maintenance dose: Titrate dose to effect; after week 4, increase dose every 1-2 weeks by a calculated increment; calculate increment as 1.2 mg/kg/day rounded down to the nearest whole tablet; add this amount to the previously administered daily dose; usual maintenance: 5-15 mg/kg/day in 2 divided doses; maximum: 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &gt;12 years, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Patients receiving AEDs",
"      <b>",
"       <span style=\"text-decoration: underline\">",
"        other than",
"       </span>",
"      </b>",
"     </i>",
"     <b>",
"      <i>",
"       carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 1 and 2: 25 mg every day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 3 and 4: 50 mg every day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Maintenance dose: Titrate dose to effect; after week 4, increase dose every 1-2 weeks by 50 mg/day; usual maintenance: 225-375 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Patients receiving AED regimens",
"      <b>",
"       containing valproic acid",
"      </b>",
"      :",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 1 and 2: 25 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 3 and 4: 25 mg every day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Maintenance dose: Titrate dose to effect; after week 4, increase dose every 1-2 weeks by 25-50 mg/day; usual maintenance in patients receiving valproic acid and other drugs that induce glucuronidation: 100-400 mg/day in 1-2 divided doses; usual maintenance in patients adding lamotrigine to valproic acid",
"     <b>",
"      alone",
"     </b>",
"     : 100-200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Patients receiving",
"      <b>",
"       enzyme-inducing",
"      </b>",
"      AED regimens (eg, carbamazepine, phenytoin, phenobarbital, or primidone)",
"      <b>",
"       without valproic acid",
"      </b>",
"      :",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 1 and 2: 50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 3 and 4: 100 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Maintenance dose: Titrate dose to effect; after week 4, increase dose every 1-2 weeks by 100 mg/day; usual maintenance: 300-500 mg/day in 2 divided doses; doses as high as 700 mg/day in 2 divided doses have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release formulation: Adolescents &ge;13 years and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Dose increases after week 8 should not exceed 100 mg/day at weekly intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Regimens",
"      <b>",
"       not containing",
"      </b>",
"      carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid:",
"     </i>",
"     Initial: Weeks 1 and 2: 25 mg once daily; Weeks 3 and 4: 50 mg once daily; Week 5: 100 mg once daily; Week 6: 150 mg once daily; Week 7: 200 mg once daily; Maintenance: 300-400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Regimens",
"      <b>",
"       containing",
"      </b>",
"      valproic acid:",
"     </i>",
"     Initial: Weeks 1 and 2: 25 mg every other day; Weeks 3 and 4: 25 mg once daily; Week 5: 50 mg once daily; Week 6: 100 mg once daily; Week 7: 150 mg once daily; Maintenance: 200-250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Regimens",
"      <b>",
"       containing",
"      </b>",
"      carbamazepine, phenytoin, phenobarbital, or primidone and",
"      <b>",
"       without",
"      </b>",
"      valproic acid:",
"     </i>",
"     Initial: Weeks 1 and 2: 50 mg once daily; Weeks 3 and 4: 100 mg once daily; Week 5: 200 mg once daily; Week 6: 300 mg once daily; Week 7: 400 mg once daily; Maintenance: 400-600 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Conversion from immediate release to extended release (Lamictal&reg; XR&trade;):",
"      </i>",
"     </b>",
"     Initial dose of the extended release tablet should match the total daily dose of the immediate release formulation; monitor for seizure control, especially in patients on AED agents. Adjust dose as needed within the recommended dosing guidelines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Anticonvulsant: Monotherapy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release formulations: Adolescents &ge;16 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Conversion from adjunctive therapy with a",
"      <b>",
"       single enzyme-inducing",
"      </b>",
"      AED (eg, carbamazepine, phenytoin, phenobarbital, or primidone and",
"      <b>",
"       not valproate",
"      </b>",
"      ) to lamotrigine immediate release monotherapy:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     First add lamotrigine and titrate it (as outlined below) to the recommended maintenance monotherapy dose (500 mg/day in 2 divided doses), while maintaining the enzyme-inducing AED at a fixed level; then gradually taper the enzyme-inducing AED by 20% decrements each week to fully withdraw over a 4-week period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Weeks 1 and 2: 50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Weeks 3 and 4: 100 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Maintenance dose: After week 4, increase dose every 1-2 weeks by 100 mg/day; recommended maintenance monotherapy dose: 500 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Conversion from adjunctive therapy with",
"      <b>",
"       valproate",
"      </b>",
"      to lamotrigine immediate release monotherapy:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     This is a 4-step conversion process to achieve the lamotrigine recommended monotherapy dose (500 mg/day in 2 divided doses).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <b>",
"      First:",
"     </b>",
"     Add lamotrigine and titrate it to a dose of 200 mg/day as follows (if not already receiving 200 mg/day), while maintaining the valproate dose at a fixed level:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 1 and 2: 25 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 3 and 4: 25 mg every day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Then increase dose every 1-2 weeks by 25-50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <b>",
"      Second:",
"     </b>",
"     Keep lamotrigine dose at 200 mg/day; slowly taper valproate dose in decrements of &le;500 mg/day per week, to a dose of 500 mg/day; maintain this dose for one week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <b>",
"      Third:",
"     </b>",
"     Increase lamotrigine to 300 mg/day and decrease valproate to 250 mg/day; maintain this dose for one week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <b>",
"      Fourth:",
"     </b>",
"     Discontinue valproate and increase lamotrigine by 100 mg/day at weekly intervals to achieve recommended maintenance monotherapy dose of 500 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Conversion from adjunctive therapy with AEDs other than enzyme-inducing AEDs or valproate to lamotrigine immediate release monotherapy:",
"     </i>",
"     No specific guidelines available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release formulation: Adolescents &ge;13 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Conversion from adjunctive therapy with AEDs",
"      <b>",
"       other than",
"      </b>",
"      enzyme-inducing AEDs or valproate  to lamotrigine extended release monotherapy:",
"     </i>",
"     First add lamotrigine and titrate it (as outlined below) to a recommended lamotrigine dose of 250-300 mg once daily, while maintaining the concomitant AED at a fixed level; then gradually taper the concomitant AED by 20% decrements each week to fully withdraw over a 4-week period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Weeks 1 and 2: 25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Weeks 3 and 4: 50 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Week 5: 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Week 6: 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Week 7: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Maintenance: 250-300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Conversion from adjunctive therapy with",
"      <b>",
"       valproate",
"      </b>",
"      to lamotrigine extended release monotherapy:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     This is a 4-step conversion process to achieve the lamotrigine recommended extended release monotherapy dose (250-300 mg once daily).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <b>",
"      First:",
"     </b>",
"     Add lamotrigine and titrate it to a dose of 150 mg/day as follows (if not already receiving 150 mg/day), while maintaining the valproate dose at a fixed level:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 1 and 2: 25 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weeks 3 and 4: 25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Week 5: 50 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Week 6: 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Week 7: 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <b>",
"      Second:",
"     </b>",
"     Keep lamotrigine dose at 150 mg/day; slowly taper valproate dose in decrements of &le;500 mg/day per week, to a dose of 500 mg/day; maintain this dose for 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <b>",
"      Third:",
"     </b>",
"     Increase lamotrigine to 200 mg/day and decrease valproate to 250 mg/day; maintain this dose for 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <b>",
"      Fourth:",
"     </b>",
"     Discontinue valproate and increase lamotrigine to a maintenance dose of 250-300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Conversion from adjunctive therapy with a",
"      <b>",
"       single enzyme-inducing",
"      </b>",
"      AED (eg, carbamazepine, phenytoin, phenobarbital, or primidone and",
"      <b>",
"       not valproate",
"      </b>",
"      )  to lamotrigine extended release monotherapy in patients with partial seizures:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     First add lamotrigine and titrate it (as outlined below) to a recommended lamotrigine dose of 500 mg/day, while maintaining the enzyme-inducing AED at a fixed level; then gradually taper the enzyme-inducing AED by 20% decrements each week to fully withdraw over a 4-week period. Two weeks following withdrawal of the enzyme-inducing AED, the dosage of lamotrigine extended release may be tapered in decrements of &le;100 mg/day at intervals of 1 week to achieve a maintenance dosage range of 250-300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Weeks 1 and 2: 50 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Weeks 3 and 4: 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Maintenance: After week 4, increase dose every 1 week by 100 mg/day to a lamotrigine dose of 500 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Bipolar disorder:",
"     </b>",
"     Oral: Immediate release formulation: Adolescents &ge;18 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients",
"      <b>",
"       not",
"      </b>",
"      receiving enzyme-inducing drugs (eg, carbamazepine, phenytoin, phenobarbital, primidone, rifampin) or valproate:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weeks 1 and 2: 25 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weeks 3 and 4: 50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Week 5: 100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Week 6 and thereafter: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients receiving",
"      <b>",
"       valproate",
"      </b>",
"      :",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weeks 1 and 2: 25 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weeks 3 and 4: 25 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Week 5: 50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Week 6 and thereafter: 100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If valproate is discontinued, increase daily lamotrigine dose in 50 mg increments at weekly intervals until dosage of 200 mg/day is attained.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients receiving",
"      <b>",
"       enzyme-inducing drugs",
"      </b>",
"      (eg, carbamazepine, phenytoin, phenobarbital, primidone, rifampin)",
"      <b>",
"       without valproate",
"      </b>",
"      :",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weeks 1 and 2: 50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weeks 3 and 4: 100 mg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Week 5: 200 mg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Week 6: 300 mg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Week 7 and thereafter: May increase to 400 mg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If carbamazepine (or other enzyme-inducing drug) is discontinued, maintain current lamotrigine dose for 1 week, then decrease daily lamotrigine dose in 100 mg increments at weekly intervals until dosage of 200 mg/day is attained.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with concomitant estrogen-containing oral contraceptives:",
"     </b>",
"     Follow initial lamotrigine dosing guidelines, maintenance dose should be adjusted as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients",
"      <b>",
"       taking",
"      </b>",
"      concomitant carbamazepine, phenytoin, phenobarbital, primidone, or other drugs, such as rifampin, that induce lamotrigine glucuronidation:",
"     </i>",
"     No dosing adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients",
"      <b>",
"       not taking",
"      </b>",
"      concomitant carbamazepine, phenytoin, phenobarbital, primidone, or other drugs, such as rifampin, that induce lamotrigine glucuronidation:",
"     </i>",
"     If already taking estrogen-containing oral contraceptives, the maintenance dose of lamotrigine may need to be increased by as much as twofold over the target maintenance dose listed above. If already taking a stable dose of lamotrigine and starting an oral contraceptive agent, the lamotrigine maintenance dose may need to be increased by as much as twofold. Dose increases should start when contraceptive agent is started and titrated to clinical response increasing no more rapidly than 50-100 mg/day every week. Gradual increases of lamotrigine plasma levels may occur during the inactive &ldquo;pill-free&rdquo; week and will be greater when dose increases are made the week before. If increased adverse events consistently occur during &ldquo;pill-free&rdquo; week, overall dose adjustments may be required. Dose adjustments during &ldquo;pill-free&rdquo; week are not recommended. When discontinuing combination hormonal contraceptive, dose of lamotrigine may need decreased by as much as 50%; do not decrease by more than 25% of total daily dose over a 2-week period unless clinical response or plasma levels indicate otherwise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Discontinuing therapy:",
"     </i>",
"     Children and Adults: Do not abruptly discontinue; when discontinuing lamotrigine therapy, gradually decrease the dose by ~50% per week and taper over at least 2 weeks unless safety concerns require a more rapid withdrawal.",
"     <b>",
"      Note:",
"     </b>",
"     If discontinuing other anticonvulsants and maintaining lamotrigine therapy, keep in mind that discontinuing carbamazepine, phenytoin, phenobarbital, primidone, or other drugs, such as rifampin, that induce lamotrigine glucuronidation should prolong the half-life of lamotrigine; discontinuing valproic acid should shorten the half-life of lamotrigine; monitor patient closely; dosage change may be needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Use with caution; has not been adequately studied; base initial dose on patient&rsquo;s AED regimen; decreased maintenance dosage may be effective in patients with significant renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Adjust escalation and maintenance doses by clinical response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild hepatic impairment: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate and severe hepatic impairment without ascites: Reduce initial, escalation, and maintenance doses by &sim;25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic impairment with ascites: Reduce initial, escalation, and maintenance doses by 50%",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 100 mg, 150 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg;: 25 mg, 100 mg, 150 mg, 200 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [combination package (each unit-dose starter kit contains)]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg;: 25 mg (84s) [white tablets] and 100 mg (14s) [peach tablets] [scored; green kit; for patients taking carbamazepine, phenytoin, phenobarbital, primidone, or rifampin and",
"     <b>",
"      not",
"     </b>",
"     taking valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg;: 25 mg (42s) [white tablets] and 100 mg (7s) [peach tablets] [scored; orange kit; for patients",
"     <b>",
"      not",
"     </b>",
"     taking carbamazepine, phenytoin, phenobarbital, primidone, rifampin, or valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [each unit-dose starter kit contains]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg;: 25 mg [scored; blue kit; for patients taking valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable/dispersible, oral: 5 mg, 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg;: 2 mg [black currant flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg;: 5 mg [scored; black currant flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg;: 25 mg [black currant flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 25 mg, 50 mg, 100 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg; XR&trade;: 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral [combination package (each patient titration kit contains)]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg; XR&trade;: 25 mg (21s) [yellow/white tablets] and 50 mg (7s) [green/white tablets] [blue XR kit, for patients taking valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg; XR&trade;: 50 mg (14s) [green/white tablets], 100 mg (14s) [orange/white tablets], and 200 mg (7s) [blue/white tablets] [green XR kit, for patients taking carbamazepine, phenytoin, phenobarbital, primidone, and",
"     <b>",
"      not",
"     </b>",
"     taking valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg; XR&trade;: 25 mg (14s) [yellow/white tablets], 50 mg (14s) [green/white tablets], and 100 mg (7s) [orange/white tablets] [orange XR kit, for patients",
"     <b>",
"      not",
"     </b>",
"     taking carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg; ODT&trade;: 25 mg, 50 mg, 100 mg, 200 mg [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral [combination package (each patient titration kit contains)]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg; ODT&trade;: 25 mg (21s) and 50 mg (7s) [cherry flavor; blue kit, for patients taking valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg; ODT&trade;: 50 mg (42s) and 100 mg (14s) [cherry flavor; green kit, for patients taking carbamazepine, phenytoin, phenobarbital, primidone, or rifampin and",
"     <b>",
"      not",
"     </b>",
"     taking valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg; ODT&trade;: 25 mg (14s), 50 mg (14s), and 100 mg (7s) [cherry flavor; orange kit, for patients",
"     <b>",
"      not",
"     </b>",
"     taking carbamazepine, phenytoin, phenobarbital, primidone, rifampin, or valproic acid]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes orally disintegrating tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information, and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lamictal&reg;, Lamictal&reg; ODT&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152835.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152835.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lamictal&reg; XR&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM166013.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM166013.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to food. If medication is received in blisterpack, examine blisterpack before use; do not use if blisters are broken, torn, or missing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Regular tablet: Do not chew, as a bitter taste may result; swallow tablet whole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chewable, dispersible tablet: Only whole tablets should be administered; may swallow whole, chew, or disperse in water or diluted fruit juice; if chewed, administer a small amount of water or diluted fruit juice to help in swallowing. To disperse, add tablets to a small amount of liquid (~5 mL or enough to cover the medication); when the tablets are completely dispersed (in about 1 minute), swirl the solution and administer the entire amount immediately. Do not attempt to administer partial quantities of dispersed tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended-release tablet (Lamictal&reg; XR&trade;): May be administered without regard to meals. Swallow tablet whole; do not chew, crush, or break.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Orally disintegrating tablet (Lamictal&reg; ODT&trade;): Place tablet on tongue and move around in the mouth. Tablet will dissolve rapidly and can be swallowed with or without food or water.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lamictal&reg; tablets and chewable dispersible tablets: Store at controlled room temperature at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); store in a dry place; protect 100 mg, 150 mg, and 200 mg tablets from light",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lamictal&reg; orally disintegrating tablets: Store between 20&deg;C to 25&deg;C (68&deg;F to  77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lamictal&reg; XR&trade; tablets: Store at controlled room temperature at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets, chewable dispersible tablets, and orally disintegrating tablets: Adjunctive treatment of generalized seizures of Lennox-Gastaut syndrome, primary generalized tonic-clonic seizures, and partial seizures (FDA approved in ages &ge;2 years and adults); monotherapy of partial seizures in patients who are converted from valproic acid or a single enzyme-inducing AED (specifically, carbamazepine, phenytoin, phenobarbital, or primidone) (FDA approved in ages &ge;16 years and adults); maintenance treatment of bipolar disorder (FDA approved in ages &ge;18 years and adults); has also been used as adjunctive treatment of partial seizures in ages &lt; 24 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended-release tablets: Adjunctive treatment of primary generalized tonic-clonic seizures and partial onset seizures with or without secondary generalization (FDA approved in ages &ge;13 years and adults); monotherapy of partial seizures in patients who are converted from a single AED (FDA approved in ages &ge;13 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Preliminary investigations have shown potential efficacy as add-on therapy for absence, atypical absence, atonic, tonic, and myoclonic seizures; and as monotherapy in adults and adolescents for idiopathic generalized tonic-clonic seizures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F186355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       LamoTRIgine may be confused with labetalol, LamISIL&reg;, lamiVUDine, levothyroxine, Lomotil&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       LaMICtal&reg; may be confused with LamISIL&reg;, Lomotil&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Potential exists for medication errors to occur among different formulations of LaMICtal&reg; (tablets, extended release tablets, orally disintegrating tablets, and chewable/dispersible tablets). Patients should be instructed to visually inspect tablets dispensed to verify receiving the correct medication and formulation. The medication guide includes illustrations to aid in tablet verification.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lamictal [U.S., Canada, and multiple international markets] may be confused with Ludiomil brand name for maprotiline [multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lamotrigine [U.S., Canada, and multiple international markets] may be confused with Ludiomil brand name for maprotiline [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F186353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema (including peripheral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, amnesia, anxiety, ataxia, confusion, depression, dizziness, dream abnormality, emotional lability, fatigue, fever, hypoesthesia, insomnia, irritability, migraine, pain , somnolence, suicidal ideation, thought abnormality",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, dry skin, rash (nonserious)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Also observed: Rash requiring hospitalization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea, libido increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, dyspepsia, flatulence, nausea, peptic ulcer, rectal hemorrhage, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, neck pain, paresthesia,  weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia, nystagmus, vision abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, dyspnea, epistaxis, pharyngitis, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis,  dyspraxia, infection, reflexes increased/decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Accommodation abnormality, agranulocytosis, alcohol intolerance, allergic reaction, alopecia, anemia, angina, angioedema, aphasia, aplastic anemia, apnea, appetite increased, arthritis, aseptic meningitis, atrial fibrillation, bruising, cerebellar syndrome, cerebral sinus thrombosis, cerebrovascular accident, chills, choreoathetosis, CNS depression/stimulation, conjunctivitis, deafness, deep thrombophlebitis, delirium, delusions,  dermatitis (exfoliative, fungal), disseminated intravascular coagulation, dysphagia, dysphoria, dystonia, ECG abnormality, ejaculation abnormal, eructation, erythema multiforme, esophagitis, euphoria, extrapyramidal syndrome, flushing, gastritis, gingivitis, goiter, hallucinations, hematuria, hemiplegia, hemolytic anemia, hemorrhage, hepatitis, hiccup, hirsutism, hot flashes, hyperalgesia, hyperglycemia, hypersensitivity reactions, hypertension, hyperventilation, hypokinesia, hypothyroidism, hypotonia, impotence, kidney failure (acute), leg cramps, leukopenia, liver function tests abnormal, lupus-like reaction, lymphadenopathy, maculopapular rash, menorrhagia, MI, mouth ulceration, movement disorder, multiorgan failure, muscle spasm, myasthenia, neuralgia, neurosis, neutropenia, orthostatic hypotension, palpitation, pancreatitis, pancytopenia, paralysis, parkinsonian exacerbation, peripheral neuritis, photophobia, polyuria, progressive immunosuppression, pruritus, pure red cell aplasia, rhabdomyolysis, salivation increased, skin discoloration, status epilepticus, Stevens-Johnson syndrome, sudden unexplained death in epilepsy (SUDEP), suicidal behavior, suicide, syncope, tachycardia, taste loss/perversion, thrombocytopenia, tic, tinnitus, tongue edema, toxic epidermal necrolysis, twitching, urinary incontinence, urticaria, vasculitis, vasodilation, withdrawal seizures",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lamotrigine or any component (eg, rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and decrease the dose in patients with renal or moderate to severe hepatic dysfunction. Use with caution in patients with impaired cardiac function (clinical experience is limited). Use with caution and adjust the dose in patients receiving estrogen-containing oral contraceptives; estrogen-containing oral contraceptives may decrease the serum concentration of lamotrigine; dosage adjustment of lamotrigine will be necessary in most women when starting or stopping estrogen-containing oral contraceptives. Valproic acid may cause an increase in lamotrigine serum concentrations requiring dose adjustment. Patients treated for bipolar disorder should be monitored closely for clinical worsening of depressive symptoms or suicidality, especially with initiation of therapy or dosage changes; prescriptions should be written for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Do not abruptly discontinue; when discontinuing therapy, gradually reduce the dose by ~50% per week and taper over at least 2 weeks unless safety concerns require a more rapid withdrawal. Lamotrigine should",
"     <b>",
"      not",
"     </b>",
"     be restarted in patients who discontinued therapy due to lamotrigine-associated rash, unless benefits clearly outweigh risks; if restarting lamotrigine after withholding for &gt;5 half-lives, use the initial dosing recommendations and titrate dosage accordingly (ie, do",
"     <b>",
"      not",
"     </b>",
"     restart at the previous maintenance dose). Lamotrigine binds to melanin and may possibly accumulate in the eye and other tissues rich in melanin; long-term ophthalmologic effects are unknown. A potential for the occurrence of medication errors exists with similar-sounding medications and among the different lamotrigine formulations.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Lamotrigine is",
"     <b>",
"      not",
"     </b>",
"     approved for acute treatment of mood episodes or for use in epilepsy as initial monotherapy, conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid, or for conversion to monotherapy from 2 or more AEDs. A small randomized, double-blind, placebo-controlled study in pediatric patients 1-24 months of age did",
"     <b>",
"      not",
"     </b>",
"     demonstrate safety and efficacy of immediate-release lamotrigine when used as adjunctive treatment for partial seizures; lamotrigine was associated with an increased risk for infectious and respiratory adverse reactions.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Skin rash may occur (10% incidence in patients with epilepsy; 14% incidence in patients with bipolar disorder). Skin rash can be serious enough to require hospitalization or discontinuation of drug",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; serious skin rashes (including Stevens-Johnson syndrome) occur in 0.8% of pediatric epilepsy patients (2-16 years of age) and 0.3% of adult epilepsy patients and in up to 0.13% of adult patients treated for bipolar and other mood disorders; rare cases of toxic epidermal necrolysis have been reported; rash-related deaths have occurred in pediatric and adult patients. In addition to pediatric age, the risk of rash may be increased in patients receiving valproic acid, high initial doses, or with rapid dosage increases; rash usually appears in the first 2-8 weeks of therapy, but may occur after prolonged treatment (eg, 6 months). Benign rashes may occur, but one cannot predict which rashes will become serious or life-threatening; the manufacturer recommends (ordinarily) discontinuation of lamotrigine at the first sign of rash (unless rash is clearly not drug related); discontinuation of lamotrigine may not prevent rash from becoming life-threatening or permanently disfiguring or disabling. Risk of nonserious rash may also be increased when the initial recommended dose or dose escalation rate is exceeded in patients with a history of rash or allergy to other AEDs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Increased risk of developing aseptic meningitis has been reported with lamotrigine use; symptoms (eg, headache, nuchal rigidity, fever, nausea/vomiting, rash, photophobia) have generally occurred within 1-45 days following therapy initiation. In some cases, new onset hepatic, renal, and/or other organ involvement has also occurred with symptoms, possibly suggesting aseptic meningitis is associated with a hypersensitivity reaction.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Potentially fatal hypersensitivity reactions may occur; these may include multiorgan failure or dysfunction; early symptoms of hypersensitivity reaction (eg, lymphadenopathy, fever) may occur without rash; discontinue lamotrigine if another cause for symptoms cannot be established. Blood dyscrasias may occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Preliminary data from the North American Antiepileptic Drug Pregnancy Registry (NAAED) suggest a possible association of lamotrigine exposure in the first trimester of pregnancy with an increased chance of cleft lip and/or cleft palate. More research and data collection is needed to confirm this possible association. Pregnant women who are currently taking lamotrigine or who are thinking about taking lamotrigine should talk with their physician first, before stopping or starting this medication.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5-100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA  requires a Medication Guide for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F186271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of LamoTRIgine. Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: LamoTRIgine may enhance the adverse/toxic effect of CarBAMazepine. CarBAMazepine may increase the metabolism of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the serum concentration of LamoTRIgine. Management: Monitor for increased serum concentrations/effects of lamotrigine in patients in whom a hormonal contraceptive is discontinued/dose decreased (this includes during a pill-free week). A reduced dosage of lamotrigine may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): LamoTRIgine may decrease the serum concentration of Contraceptives (Progestins).  Management: Women using progestin-only &ldquo;minipill&rdquo; products may be at risk for contraceptive failure; it is unclear if other progestin-containing products would be significantly impacted.  Alternative, non-hormonal, means of contraception are recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: LamoTRIgine may enhance the adverse/toxic effect of Desmopressin. LamoTRIgine may enhance the therapeutic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May enhance the adverse/toxic effect of LamoTRIgine. Divalproex may increase the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: LamoTRIgine may increase the serum concentration of MetFORMIN.  Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: LamoTRIgine may enhance the sedative effect of OLANZapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of LamoTRIgine. Management: Adjust dose per lamotrigine prescribing information guidelines during primidone treatment.  Monitor for decreased concentration/effect if primidone is initiated/dose increased or increased concentration/effect if primidone is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: LamoTRIgine may increase the serum concentration of Procainamide.  Management: Consider monitoring for increased procainamide concentrations and/or systemic effects in patients receiving procainamide with lamotrigine.  The lamotrigine Canadian product monograph states that coadministration of these agents is not recommended.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of LamoTRIgine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May enhance the adverse/toxic effect of LamoTRIgine. Valproic Acid may increase the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1053565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption is not affected by food",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F186273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F186289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lamotrigine has been found to decrease folate concentrations in animal studies. Teratogenic effects in animals were not observed. Lamotrigine crosses the human placenta and can be measured in the plasma of exposed newborns. Preliminary data from the North American Antiepileptic Drug Pregnancy Registry (NAAED) suggest an increased incidence of cleft lip and/or cleft palate following first trimester exposure. Healthcare providers may enroll patients in the Lamotrigine Pregnancy Registry by calling (800) 336-2176. Patients may enroll themselves in the NAAED registry by calling (888) 233-2334. Additional information is available at www.aedpregnancyregistry.org. Dose of lamotrigine may need adjustment during pregnancy to maintain clinical response; lamotrigine serum levels may decrease during pregnancy and return to prepartum levels following delivery. Monitor frequently during pregnancy, following delivery, and when adding or discontinuing combination hormonal contraceptives.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     All patients: Monitor for hypersensitivity reactions, especially rash; CBC with differential; liver and renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Epilepsy: Seizure frequency, duration, and severity; serum levels of concurrent anticonvulsants; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bipolar disorder: Clinical worsening of depressive symptoms or suicidality, especially with initiation of therapy or dosage changes",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1053556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The clinical value of monitoring lamotrigine plasma concentrations has not been established. Dosing should be based on therapeutic response. Proposed therapeutic range: 1-5 mcg/mL. Lamotrigine plasma concentrations of 0.25-29.1 mcg/mL have been reported in the literature.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A triazine derivative which affects voltage-sensitive sodium channels and inhibits presynaptic release of glutamate and aspartate (excitatory amino acid CNS neurotransmitters); mechanism of action for treatment of bipolar disorder has not been established",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Immediate release: Rapid, 97.6% absorbed;",
"     <b>",
"      Note:",
"     </b>",
"     Orally disintegrating tablets (either swallowed whole with water or disintegrated in the mouth) are equivalent to regular tablets (swallowed whole with water) in terms of rate and extent of absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 1.1 L/kg; range: 0.9-1.3 L/kg; crosses into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 55% (primarily albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: &gt;75% metabolized in the liver via glucuronidation; autoinduction may occur",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Immediate release: 98%;",
"     <b>",
"      Note:",
"     </b>",
"     AUCs were similar for immediate release and extended release preparations in patients receiving nonenzyme-inducing AEDs. In subjects receiving concomitant enzyme-inducing AEDs,  bioavailability of extended release product was ~21% lower than immediate-release product; in some of these subjects, a decrease in AUC of up to 70% was observed when switching from immediate-release to extended-release tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     With enzyme-inducing AEDs (ie, phenytoin, phenobarbital, carbamazepine, primidone):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants 10 months of age to children 5.3 years: 7.7 hours (range: 6-11 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 5-11 years: 7 hours (range: 4-10 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     With enzyme-inducing AED and valproic acid (VPA): Children 5-11 years: 19 hours (range: 7-31 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     With VPA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants 10 months of age to children 5.3 years: 45 hours (range: 30-52 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 5-11 years: 66 hours (range: 50-74 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Normal: Single dose: 33 hours; multiple dose: &sim;25 hours (range: 12-62 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     With enzyme-inducing AEDs: 13 hours (range: 8-23 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     With enzyme-inducing AED and VPA: &sim;27 hours (range: 11-52 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     With VPA: 59 hours (range: 30-89 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hepatic dysfunction: Child-Pugh classification:",
"    </p>",
"    <p style=\"text-indent:-6em;margin-left:12em;text-align:justify;\">",
"     Mild liver impairment: 46 &plusmn; 20 hours",
"    </p>",
"    <p style=\"text-indent:-6em;margin-left:12em;text-align:justify;\">",
"     Moderate liver impairment: 72 &plusmn; 44 hours",
"    </p>",
"    <p style=\"text-indent:-6em;margin-left:12em;text-align:justify;\">",
"     Severe liver impairment without ascites: 67&plusmn; 11 hours",
"    </p>",
"    <p style=\"text-indent:-6em;margin-left:12em;text-align:justify;\">",
"     Severe liver impairment with ascites: 100 &plusmn; 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     13 mL/minute): &sim;43 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute): 57.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     During dialysis: 13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Immediate release: ~2 hours (range: 1.4-4.8 hours); select patients may have second peak at 4-6 hours due to enterohepatic recirculation. Extended release: 4-11 hours (dependent on adjunct therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 75% to 90% excreted as glucuronide metabolites and 10% as unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: &sim;20% is removed during 4-hour hemodialysis period",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/40/41605?source=see_link\">",
"      see \"Lamotrigine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of lamotrigine. Carefully look at your medication after each refill; contact the prescriber if the medication looks different or the label name has changed. Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you feel more depressed or have thoughts of suicide or self harm. Take exactly as directed; do not increase dose or frequency or discontinue without consulting prescriber. Do not abruptly discontinue therapy (an increase in seizure activity may result). Taking other medications may require a dosage change in lamotrigine; report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist; do not use alcohol and other prescription or OTC medications (especially pain medications, sedatives, antihistamines, or hypnotics) without consulting prescriber. Notify physician if you will be starting or stopping oral contraceptives or other female hormonal products (a dosage adjustment of lamotrigine may be needed; efficacy of oral contraceptives may be decreased; report any changes in menstrual pattern such as breakthrough bleeding). Report any rash, fever, or swelling of glands to the physician immediately (skin rash may indicate a serious medical problem). Lamotrigine may cause dizziness, drowsiness, or blurred vision and impair ability to perform activities requiring mental alertness or physical coordination. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs. Report CNS changes, mentation changes, or changes in cognition; signs and symptoms of meningitis (headache, fever, nausea, vomiting, stiff neck, abnormal sensitivity to light, muscle pain, chills); persistent GI symptoms (cramping, constipation, vomiting, anorexia); swelling of face, lips, or tongue; easy bruising or bleeding (mouth, urine, stool); vision changes; worsening of seizure activity, or loss of seizure control to prescriber.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low water solubility. Does",
"     <b>",
"      not",
"     </b>",
"     induce P450 microsomal enzymes. The clinical usefulness of lamotrigine should be periodically re-evaluated in patients with bipolar disorder who are receiving the drug for extended intervals (ie, &gt;16 weeks).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The extended-release tablets contain a modified-release eroding formulation as the core of the tablet. The clear enteric coating has an aperture drilled through it on both sides of the tablet; this allows an extended release of the medication in the acidic environment within the stomach. The design of the table controls the dissolution rate of the medication over a 12-15 hour period.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Three different lamotrigine &ldquo;Starter Kits&rdquo; are available for adult patients for three different dosage forms (tablets, extended release tablets, and orally disintegrating tablets); each starter kit contains a blisterpack with a certain number and mg strength of tablets that are specific for initiating doses in different patient populations.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F186284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL oral suspension may be made with tablets and one of two different vehicles (a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;). Crush one 100 mg tablet in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a graduated cylinder, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Label \"shake well\" and \"protect from light\". Stable for 91 days when stored in amber plastic prescription bottles in the dark at room temperature or refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata M, Morosco R, Hipple T. &ldquo;Stability of Lamotrigine in Two Extemporaneously Prepared Oral Suspensions at 4 and 25 Degrees C,&rdquo;",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1999, 56(3):240-2.",
"     <span class=\"pubmed-id\">",
"      10030509",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barr PA, Buettiker VE, and Antony JH, \"Efficacy of Lamotrigine in Refractory Neonatal Seizures,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 1999, 20(2):161-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/34/3626/abstract-text/10082350/pubmed\" id=\"10082350\" target=\"_blank\">",
"        10082350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Battino D, Estienne M, and Avanzini G, &ldquo;Clinical Pharmacokinetics of Antiepileptic Drugs in Paediatric Patients: Part II. Phenytoin, Carbamazepine, Sulthiame, Lamotrigine, Vigabatrin, Oxcarbazepine, and Felbamate,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 29(5):341-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/34/3626/abstract-text/8582119 /pubmed\" id=\"8582119 \" target=\"_blank\">",
"        8582119",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Besag FM, Wallace SJ, Dulac O, et al, &ldquo;Lamotrigine for the Treatment of Epilepsy in Childhood,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1995, 127(6):991-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/34/3626/abstract-text/8523205/pubmed\" id=\"8523205\" target=\"_blank\">",
"        8523205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burstein AH, &ldquo;Lamotrigine,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1995, 15(2):129-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/34/3626/abstract-text/7624259/pubmed\" id=\"7624259\" target=\"_blank\">",
"        7624259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dooley J, Camfield P, Gordon K, et al, &ldquo;Lamotrigine-Induced Rash in Children,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1996, 46(1):240-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/34/3626/abstract-text/8559384 /pubmed\" id=\"8559384 \" target=\"_blank\">",
"        8559384",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fitton A, and Goa KL, &ldquo;Lamotrigine: An Update of its Pharmacology and Therapeutic Use in Epilepsy,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1995, 50(4):691-713.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/34/3626/abstract-text/8536554/pubmed\" id=\"8536554\" target=\"_blank\">",
"        8536554",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Messenheimer JA, &ldquo;Lamotrigine,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1995, 36(Suppl 2):S87-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/34/3626/abstract-text/8784217/pubmed\" id=\"8784217\" target=\"_blank\">",
"        8784217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Messenheimer JA, Giorgi L, and Risner ME, &ldquo;The Tolerability of Lamotrigine in Children,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2000, 22(4):303-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/34/3626/abstract-text/10789824/pubmed\" id=\"10789824\" target=\"_blank\">",
"        10789824",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mikati MA, Fayad M, Koleilat M, et al, \"Efficacy, Tolerability, and Kinetics of Lamotrigine in Infants,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2002, 141(1):31-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/34/3626/abstract-text/12091848/pubmed\" id=\"12091848\" target=\"_blank\">",
"        12091848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pi&ntilde;a-Garza JE, Elterman RD, Ayala R, et al, \"Long-Term Tolerability and Efficacy of Lamotrigine in Infants 1 to 24 Months Old,\"",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 2008, 23(8):853-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/34/3626/abstract-text/18660469/pubmed\" id=\"18660469\" target=\"_blank\">",
"        18660469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pi&ntilde;a-Garza JE, Levisohn P, Gucuyener K, et al, \"Adjunctive Lamotrigine for Partial Seizures in Patients Aged 1 to 24 Months,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2008a, 70(22 Pt 2):2099-108.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/34/3626/abstract-text/18077797/pubmed\" id=\"18077797\" target=\"_blank\">",
"        18077797",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12542 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A20BFA4EA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_34_3626=[""].join("\n");
var outline_f3_34_3626=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709006\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186304\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186305\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053553\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675197\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053546\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186277\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186262\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874647\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053558\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053549\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053557\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186355\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186353\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053562\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053545\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053544\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299573\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186271\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053565\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186273\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186289\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053552\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053556\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053543\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053561\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053551\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053563\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186284\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12542\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12542|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=related_link\">",
"      Lamotrigine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/40/41605?source=related_link\">",
"      Lamotrigine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_34_3627="Risk of breast and ovarian cancer for women with BRCA mutations";
var content_f3_34_3627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lifetime risk of breast and ovarian cancer for women with BRCA mutations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lifetime risk of breast cancer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lifetime risk of ovarian cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         BRCA1 mutation",
"        </strong>",
"       </td>",
"       <td>",
"        55 to 85 percent",
"       </td>",
"       <td>",
"        35 to 46 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         BRCA2 mutation",
"        </strong>",
"       </td>",
"       <td>",
"        50 to 85 percent",
"       </td>",
"       <td>",
"        13 to 23 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_34_3627=[""].join("\n");
var outline_f3_34_3627=null;
var title_f3_34_3628="TTE in chronic MR";
var content_f3_34_3628=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Transthoracic echocardiography in patients with patients with chronic mitral regurgitation (MR)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that TTE is indicated in patients with chronic MR in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; If MR is suspected, for baseline evaluation of left ventricular size and function, left atrial and right ventricular size, pulmonary artery pressure, and severity of MR.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; For determination of the mechanism of MR.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; In asymptomatic patients with severe MR, every 6 to 12 months for surveillance of left ventricular function, as estimated by left ventricular ejection fraction and left ventricular end-systolic dimension. Among asymptomatic patients with moderate MR, every 12 months or sooner if symptoms occur.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; After a change in signs or symptoms, for evaluation of the mitral valve apparatus and left ventricular function.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull;  At the initial evaluation after mitral valve repair or mitral valve replacement, for evaluation of left ventricular size and function and hemodynamics across the mitral valve.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The weight of evidence or opinion is in favor of the usefulness of TTE in patients with chronic MR in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; In asymptomatic patients with severe MR, exercise Doppler echocardiography to assess both exercise tolerance and the effect of exercise on both pulmonary artery pressure and MR severity.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class III - There is evidence and/or general agreement that TTE is not useful in patients with chronic MR in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Routine follow-up of patients with asymptomatic mild MR who have normal left ventricular size and function.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_34_3628=[""].join("\n");
var outline_f3_34_3628=null;
var title_f3_34_3629="Func out men rad cystect";
var content_f3_34_3629=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Functional studies in men undergoing radical cystectomy and orthotopic reconstruction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Author, year",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Number of patients, percent male",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Median follow-up, months",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Continence rate, percent",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Intermittent catheterization needed, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Day",
"       </td>",
"       <td class=\"subtitle2\">",
"        Night",
"       </td>",
"       <td class=\"subtitle2\">",
"        Time of assessment*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barre, P; 1996",
"       </td>",
"       <td>",
"        110 (100)",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cancrini, A; 1996",
"       </td>",
"       <td>",
"        96 (93)",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        One year",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elmajian, D; 1996",
"       </td>",
"       <td>",
"        295 (100)",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        One year",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hautmann, R; 1999",
"       </td>",
"       <td>",
"        363 (100)",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Steven, K; 2000",
"       </td>",
"       <td rowspan=\"2\">",
"        166 (100)",
"       </td>",
"       <td rowspan=\"2\">",
"        32",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        Three year",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        Five year",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abol-Enein, H; 2001",
"       </td>",
"       <td>",
"        450 (78)",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Madersbacher, S; 2002",
"       </td>",
"       <td>",
"        176 (100)",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        Five year",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carrion, R; 2004",
"       </td>",
"       <td>",
"        138 (82)",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sevin, G; 2004",
"       </td>",
"       <td>",
"        124 (100)",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        Four year",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stein, J; 2004",
"       </td>",
"       <td>",
"        209 (81)",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        25&bull;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NR: not reported.",
"     <br>",
"      * Time point at which all patients were assessed following surgery.",
"      <br>",
"       &bull; 20 percent of men and 43 percent of women.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_34_3629=[""].join("\n");
var outline_f3_34_3629=null;
var title_f3_34_3630="Comparison IIV LAIV";
var content_f3_34_3630=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Live attenuated influenza vaccine (LAIV) compared with inactivated influenza vaccine (IIV) for seasonal influenza, United States formulations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Factor",
"       </td>",
"       <td class=\"subtitle1\">",
"        LAIV",
"       </td>",
"       <td class=\"subtitle1\">",
"        IIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Route of administration",
"       </td>",
"       <td>",
"        Intranasal spray",
"       </td>",
"       <td>",
"        Intramuscular injection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type of vaccine",
"       </td>",
"       <td>",
"        Live virus",
"       </td>",
"       <td>",
"        Killed virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number of included virus strains",
"       </td>",
"       <td>",
"        Three (two influenza A, one influenza B) or four (two influenza A, two influenza B)",
"       </td>",
"       <td>",
"        Three (two influenza A, one influenza B) or four (two influenza A, two influenza B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vaccine virus strains updated",
"       </td>",
"       <td>",
"        Annually*",
"       </td>",
"       <td>",
"        Annually*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequency of administration",
"       </td>",
"       <td>",
"        Annually",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Annually",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Approved age",
"       </td>",
"       <td>",
"        Persons aged 2 to 49 years",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Persons aged &ge;6 months",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interval between two doses recommended for children aged &ge;6 months to 8 years who require two doses",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &ge;4 weeks",
"       </td>",
"       <td>",
"        &ge;4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can be given to persons with medical risk factors for influenza-related complications",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can be given to children with asthma or children aged 2 to 4 years with wheezing in the past year",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can be administered to family members or close contacts of immunosuppressed persons not requiring a protected environment",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can be administered to family members or close contacts of immunosuppressed persons requiring a protected environment (eg, hematopoietic stem cell transplant recipient)",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can be administered to family members or close contacts of persons at higher risk including pregnant women, but not severely immunosuppressed",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can be administered simultaneously with other vaccines",
"       </td>",
"       <td>",
"        Yes",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        Yes",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If not administered simultaneously, can be administered within 4 weeks of another live vaccine",
"       </td>",
"       <td>",
"        Prudent to space &ge;4 weeks apart",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If not administered simultaneously, can be administered within 4 weeks of an inactivated vaccine",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A decision is made annually regarding which virus strains will be targeted in the vaccine for the upcoming influenza season. Even in years in which the vaccine composition is the same as the previous season, annual vaccination is necessary since immunity wanes.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Children aged six months through eight years who did not receive at least two doses of seasonal influenza vaccine&nbsp;after July 2010&nbsp;should receive two doses at least four weeks apart for the 2012-13 season. Those children aged six months through eight years who received &ge;2 doses of seasonal influenza vaccine after July 2010&nbsp;require one dose for the 2012-13 season.",
"      <br>",
"       &Delta; Persons at higher risk for complications of influenza infection because of underlying medical conditions should not receive LAIV. Such persons include those who have chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, neurologic, neuromuscular, and neurodevelopmental disorders (including disorders of the brain, spinal cord, peripheral nerve and muscle such as cerebral palsy, epilepsy, stroke, intellectual disability [mental retardation], moderate to severe developmental delay, muscular dystrophy, or spinal cord injury), hematologic, or metabolic (including diabetes mellitus) disorders; those who are immunosuppressed (including immunosuppression caused by medications or by human immunodeficiency virus); those who are or will be pregnant during the influenza season; those aged 6 months to 18 years and receiving long-term aspirin therapy and who therefore might be at risk for experiencing Reye syndrome after influenza virus infection; and residents of nursing homes and other chronic-care facilities.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Approval varies by formulation.",
"        <br>",
"         &sect; Clinicians and vaccination programs should screen for possible reactive airways diseases when considering use of LAIV for children aged two to four years and should avoid use of this vaccine in children with asthma or a recent wheezing episode. Health-care providers should consult the medical record, when available, to identify children aged two to four years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be at greater risk for asthma and possibly at increased risk for wheezing after receiving LAIV, parents or caregivers of children aged two to four years should be asked: \"In the past 12 months, has a health-care provider ever told you that your child had wheezing or asthma?\" Children whose parents or caregivers answer \"yes\" to this question and children who have asthma or who had a wheezing episode noted in the medical record within the preceding 12 months should not receive LAIV.",
"         <br>",
"          &yen; LAIV coadministration has been evaluated systematically only among children aged 12 to15 months who received with measles, mumps and rubella vaccine or varicella vaccine.",
"          <br>",
"           &Dagger; Inactivated influenza vaccine coadministration has been evaluated systematically only among adults who received pneumococcal polysaccharide or zoster vaccine.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1.",
"       </li>",
"       <li>",
"        Centers for Disease Control and Prevention (CDC). Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1128.",
"       </li>",
"       <li>",
"        Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61:613.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_34_3630=[""].join("\n");
var outline_f3_34_3630=null;
var title_f3_34_3631="CCK and gastrin homology";
var content_f3_34_3631=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Molecular forms of cholecystokinin (CCK) and gastrin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 422px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Amino acid sequences of CCK-58, -33, and -8, and gastrin-34 and -17, all of which are biologically active. All forms of CCK and gastrin share an identical carboxyl terminal pentapeptide sequence (highlighted in the boxes).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_34_3631=[""].join("\n");
var outline_f3_34_3631=null;
         